

09/936382  
JC03 Rec'd PCT/TO 10 SEP 2001

In re U.S. National application of: TEPNEL MEDICAL LIMITED

Inventor(s): Conor MULROONEY and John Douglas OULTRAM

For: ENZYMATICALLY CATALYSED SIGNAL AMPLIFICATION

**\*\*this application claims priority from  
PCT/GB00/00921 filed March 13, 2000  
and  
British Appln. No. 9905580.8 filed March 12, 1999\*\***

Our Docket No. 3551 P 003

ENCLOSED: POSTCARD

CHECK IN THE AMOUNT OF \$645

PRELIMINARY AMENDMENT

3-PAGE ORIGINALLY-EXECUTED DECLARATION/POWER OF ATTORNEY

NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY  
DOCUMENT

NOTICE INFORMING APPLICANT OF COMMUNICATION OF INTERNATIONAL  
APPLICATION TO DESIGNATED OFFICES

INFORMATION CONCERNING ELECTED OFFICES NOTIFIED OF THEIR ELECTION

RECEIPT OF DEMAND

PCT APPLICATION AS PUBLISHED (WITH SEARCH REPORT)

I HEREBY CERTIFY THAT THIS PAPER AND THE ABOVE DOCUMENTS ARE BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS EXPRESS MAIL, POSTAGE PREPAID, IN AN ENVELOPE ADDRESSED TO BOX PCT (PCT APPLICATION/WITH FEE), COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231, ON September 10, 2001 UNDER EXPRESS MAIL NO. EL590259276US.

*Lisa M. Frankli*

**PLEASE ADDRESS ALL FUTURE COMMUNICATIONS TO:**

**MONIQUE A. MORNEAULT, ESQ.  
WALLENSTEIN & WAGNER  
311 South Wacker Drive - 5300  
Chicago, IL 60606  
(312) 554-3300**

# INTERNATIONAL SEARCH REPORT

Inter: Application No  
PCT/GB 00/00921

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	W0 98 02580 A (TM TECHNOLOGIES INC) 22 January 1998 (1998-01-22) the whole document	1-29
A	US 5 451 503 A (HOGAN JAMES J ET AL) 19 September 1995 (1995-09-19) figures 15-18; examples 8-14	1-29
A	W0 97 42346 A (TEPNEL MEDICAL LTD ;MINTER STEPHEN JOHN (GB); OULTRAM JOHN DOUGLAS) 13 November 1997 (1997-11-13) the whole document	1-29
A	US 5 681 697 A (URDEA MICHAEL S ET AL) 28 October 1997 (1997-10-28) cited in the application the whole document	1-29

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

28 August 2000

Date of mailing of the international search report

04/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Reuter, U

# INTERNATIONAL SEARCH REPORT

Inter. Application No  
PCT/GB 00/00921

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9802580 A	22-01-1998	AU 4040097 A CA 2259918 A EP 0938588 A US 5902724 A	09-02-1998 22-01-1998 01-09-1999 11-05-1999
US 5451503 A	19-09-1995	AU 665062 B AU 3586693 A CA 2128530 A DE 69328699 D EP 0552931 A JP 7503139 T WO 9315102 A US 5424413 A	14-12-1995 01-09-1993 05-08-1993 29-06-2000 28-07-1993 06-04-1995 05-08-1993 13-06-1995
WO 9742346 A	13-11-1997	AU 2646497 A	26-11-1997
US 5681697 A	28-10-1997	AU 694468 B AU 1303895 A CA 2178598 A EP 0731848 A HU 74225 A JP 9507024 T WO 9516055 A US 5635352 A	23-07-1998 27-06-1995 15-06-1995 18-09-1996 28-11-1996 15-07-1997 15-06-1995 03-06-1997

PATENT COOPERATION TREATY  
**PCT**

**INTERNATIONAL SEARCH REPORT**

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>M98/0599/PCT</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/GB 00/ 00921</b>	International filing date (day/month/year) <b>13/03/2000</b>	(Earliest) Priority Date (day/month/year) <b>12/03/1999</b>
Applicant <b>TEPNEL MEDICAL LIMITED et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 2 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

# INTERNATIONAL SEARCH REPORT

International Application No

/GB 00/00921

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	W0 98 02580 A (TM TECHNOLOGIES INC) 22 January 1998 (1998-01-22) the whole document ----	1-29
A	US 5 451 503 A (HOGAN JAMES J ET AL) 19 September 1995 (1995-09-19) figures 15-18; examples 8-14 ----	1-29
A	W0 97 42346 A (TEPNEL MEDICAL LTD ;MINTER STEPHEN JOHN (GB); OULTRAM JOHN DOUGLAS) 13 November 1997 (1997-11-13) the whole document ----	1-29
A	US 5 681 697 A (URDEA MICHAEL S ET AL) 28 October 1997 (1997-10-28) cited in the application the whole document -----	1-29

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
"&" document member of the same patent family

Date of the actual completion of the international search

28 August 2000

Date of mailing of the international search report

04/09/2000

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Reuter, U

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

GB 00/00921

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9802580	A	22-01-1998	AU 4040097 A	09-02-1998
			CA 2259918 A	22-01-1998
			EP 0938588 A	01-09-1999
			US 5902724 A	11-05-1999
US 5451503	A	19-09-1995	AU 665062 B	14-12-1995
			AU 3586693 A	01-09-1993
			CA 2128530 A	05-08-1993
			DE 69328699 D	29-06-2000
			EP 0552931 A	28-07-1993
			JP 7503139 T	06-04-1995
			WO 9315102 A	05-08-1993
			US 5424413 A	13-06-1995
WO 9742346	A	13-11-1997	AU 2646497 A	26-11-1997
US 5681697	A	28-10-1997	AU 694468 B	23-07-1998
			AU 1303895 A	27-06-1995
			CA 2178598 A	15-06-1995
			EP 0731848 A	18-09-1996
			HU 74225 A	28-11-1996
			JP 9507024 T	15-07-1997
			WO 9516055 A	15-06-1995
			US 5635352 A	03-06-1997

# PATENT COOPERATION TREATY

09/936382

PCT

REC'D 24 APR 2002

WIPO PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

#lep  
7/10/02

Applicant's or agent's file reference M98/0599/PCT		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB00/00921	International filing date (day/month/year) 13/03/2000	Priority date (day/month/year) 12/03/1999	
International Patent Classification (IPC) or national classification and IPC C12Q1/68		<b>RECEIVED</b> JUL 09 2002	
Applicant TEPNEL MEDICAL LIMITED et al.		TECH CENTER 1600/2900	


1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.
  - ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 18 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

**CORRECTED  
VERSION**

Date of submission of the demand 02/10/2000	Date of completion of this report 22.06.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Barz, W Telephone No. +49 89 2399 7320



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/00921

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

### Description, pages:

1,3-25,27-29, 32-35 as originally filed

2,2a,30,31 as received on 14/04/2001 with letter of 10/04/2001

26 as received on 29/05/2001 with letter of 18/05/2001

### Claims, No.:

1-29 as received on 14/04/2001 with letter of 10/04/2001

### Drawings, sheets:

1/21-21/21 as originally filed

### Sequence listing part of the description, pages:

1-3, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/00921

the international application as filed has been furnished.

- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description,      pages:  
☐ the claims,      Nos.:  
☐ the drawings,      sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Yes: Claims 1-29
	No: Claims
Inventive step (IS)	Yes: Claims 1-29
	No: Claims
Industrial applicability (IA)	Yes: Claims 1-29
	No: Claims

### 2. Citations and explanations **see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/GB00/00921

**ITEM I:**

The amendments to the the description and the claims fulfill the requirements of Article 34 (2)(b) PCT.

**ITEM V:**

Reference is made to the following document:

D1: US-A-5 451 503 (HOGAN J. J. et al.), 19 September 1995.

1. NOVELTY

The present application meets the requirements of Article 33(2) PCT, because none of the available prior art documents discloses a method of detecting a target molecule having the same combinations of features as those claimed in the present application.

2. INVENTIVE STEP

The present application also appears to meet the requirements of Article 33(3) PCT for the following reasons:

- 2.1 Document D1, which is considered to represent the closest prior art, discloses (see Example 14 and Figure 18) a method for detecting a target molecule, comprising steps (i) and (ii)(b), of **claim 1** of the present application. Compared to D1, the subject-matter of claim 1 differs by the use of a 3-part amplification template (step (ii)(a)), by the removal of the 5' terminus of the amplification template (step (ii)(c)) and by the extension of the 3' terminus of the locator probe (step (ii)(d)). The effect of said differences is that the amplification moiety of the locator probe is significantly amplified, thereby drastically increasing the number of binding sites for detection probes (see Figure 3(k)). D1 achieves the same effect (amplification of the detection sequence of strand 1, see Figure 18) in a

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/GB00/00921

different way. Therefore, the technical problem to be solved by claim 1 may be regarded as how to provide an alternative method for detecting a target molecule.

Since the available prior art does not appear to provide any indication to modify the method of D1 by using a 3-part amplification template (resulting in significant extension of the 3' terminus of the locator probe), the subject-matter of present claim 1 is considered inventive in the sense of Article 33(3) PCT.

- 2.2 Similarly, the subject-matter of **claim 3** also appears to involve an inventive step (Article 33(3) PCT), because the available prior art does not suggest the use of a second 3-part amplification template (the additional difference of claim 3 compared to D1). Therefore, it would not be obvious to the skilled person to modify the method of D1 by including two 3-part amplification templates, thereby resulting in the subject-matter of present claim 3.
- 2.3 The subject-matter of **claims 5 and 11** is considered inventive for analogous reasons, because the methods of these claims also involve the 3' extension of the locator probe by using amplification templates.
- 2.4 For analogous reasons as outlined in items 2.2 and 2.3 above, the subject-matter of **claim 12** also appears to involve an inventive step (Article 33(3) PCT).
- 2.5 **Claims 2, 4, 6-10, and 13-29** are dependent on claims 1, 3, 5, 11 and/or 12 and as such also meet the requirements of the PCT with respect to inventive step (Article 33(3) PCT).

**3. INDUSTRIAL APPLICABILITY**

The subject-matter of **claims 1-29** appears to be industrially applicable in the sense of Article 33(4) PCT.

14 April 2001

- 2 -

adhere. In addition, the many hybridisation steps involved in the assembly process render the system susceptible to the production of non-specific background signal.

Other target detection systems known in the art include US 5451503, WO 98/02580. WO 97/42346 and US 5681697.

The current invention outlines a method for the amplification of a nucleic acid based signal. It involves the generation of a repeating structure containing multiple copies of a detectable sequence, and is produced through the concerted action of a polymerase (which extends the repeating structure) and a separating agent (which uncovers hybridisation sites to allow assembly of sequence repeats). The method of the invention offers the following advantages over methods existing in the art:

1. It uses a small number of inexpensive components and so avoids the high cost per assay problems associated with other signal amplification systems such as bDNA.
2. It uses a signal amplification rather than a target amplification approach and thus it overcomes contamination problems associated with many current methodologies such as PCR.
3. It is an enzymatically catalyzed process that actively assembles the signal generating structure rather than relying on the passive hybridisation-based approaches of non-enzymatic methods such as bDNA.
4. It has the ability to address RNA and DNA targets with equal efficiency without pre-treatments, unlike for example PCR which requires an initial reverse transcription step before RNA targets can be amplified.

- 2a -

5. As the process is used in conjunction with a solid phase immobilized target it has the potential to be integrated into 'cutting edge' solid phase devices such as Biochips.

As can be seen from Figure 1a, Locator probe 10 comprises binding nucleic acid moiety 11 joined by a 5'-5' linkage to amplification moiety 12. Binding nucleic acid moiety 11 hybridises target nucleic acid sequence 21 of target molecule 20. Figure 1b shows Locator probe 30 comprising binding moiety 31 which is rendered resistant to exonuclease activity by the use of 2'-O-methyl-RNA residues in its synthesis, is joined by a 5'-3' linkage to amplification moiety 32. Binding nucleic acid moiety 31 hybridises target nucleic acid sequence 21 of target molecule 20.

Figure 2 shows primary amplification template 40 comprising arranged in a 5'-3' direction extension region 41, exonuclease-resistant hybridisation region 42 and amplification moiety 43.

In the method of the first embodiment of the present invention (Figure 3), hybridisation region 42 of amplification template 40 hybridises to amplification moiety 32 of Locator probe 30 (Figure 3a). DNA polymerase activity then causes the extension of amplification moiety 32, using extension region 40 as a template strand (Figure 3b). A 5' double-strand specific exonuclease (not shown) then digests the 5' terminus of the hybridised extension region 41. Exonuclease activity is halted when the enzyme encounters exonuclease resistant hybridisation region 42 (Figure 3c). Additional amplification template 40 is then able to hybridise to extended nucleic acid signal sequence 32 (Figure 3d) and the process of extension and exonuclease digestion proceed again to give the arrangement of Figure 3e.

Having washed the reaction mixture to remove unhybridized amplification template 40, the process is then repeated using secondary amplification template 50 comprising extension region 51, hybridisation region 52 and amplification moiety 53 (Figure 3f). Hybridisation region 52 is complementary to amplification moiety 43. The steps of extension of amplification moiety 43, digestion of extension region 51 and hybridisation of additional amplification template 50 then proceed as above, to create the Secondary Structure. This incorporates large numbers of amplification moiety 53 which are available for hybridisation (Figures 3g-3j).

- 30 -

substitutions such that its incorporation renders the newly synthesised strand resistant to restriction endonuclease activity.

Restriction endonuclease activity then nicks extension region 121. In an isothermal assay format the resultant fragments is designed so as to dissociate at the operating temperature used. In a thermocycled format the temperature is elevated to allow dissociation of the fragments without concomitant dissociation of uncleaved sequences. Additional amplification template 120 is then able to hybridise to extended amplification moiety 142 and the reaction able to proceed to assemble the Primary Structure. Detection or Secondary Structure assembly is subsequently carried out by repetition of the same basic processes as described above.

#### Example 4

In the fourth embodiment of the present invention (Figure 9), target nucleic acid sequence 21 of target molecule 20 is hybridised by Binding moiety 151 (which has nucleotide modifications to render it resistant to 5' double stranded exonuclease activity when required) of Locator probe 150 (Figure 9a). Amplification moiety 152 is linked to binding nucleic acid sequence 151 by extension blocker 153 (a 3' propanol addition) such that it has an exposed 3'-OH group. When amplification moiety 152 is acting as the template strand for the synthesis of a complementary strand, the extension blocker prevents the progress of any DNA polymerase beyond the end of the amplification moiety, thereby preventing the displacement of binding moiety 151 from target nucleic acid sequence 21. Once unbound Locator probe has been removed, binding moiety 151 is optionally cross-linked to target sequence 21 prior to Primary Structure assembly.

In use, hybridisation region 161 of amplification template 160 hybridises to amplification moiety 152 (Figure 9b). Hybridisation region 161 has an exposed 3'-OH group, as does amplification moiety 152. Extension region 162 then acts as a template strand for the extension of amplification moiety 152, which in turn acts as a template strand for the extension of hybridisation region 161 as far as extension

- 31 -

blocker 153 (Figure 9c). 5' double strand exonuclease activity can then digest extended amplification template 160 as shown in this example, leaving free extended amplification moiety 152 (Figure 9d). Alternatively the amplification templates can be completely removed through the use of elevated temperature. Additionally the amplification templates can be designed so as to contain modified and unmodified restriction sites that allow endonuclease cleavage to remove the extension region of the amplification template only.

Additional amplification template 160 is then able to hybridise to extended amplification moiety 152 (Figure 9e) and extension region 162 again able to act as template strand for the synthesis of a complementary strand, extending further amplification moiety 152. Similarly, amplification moiety 152 is able act as template strand for the extension of hybridisation region 161 (Figure 9f). Removal of part or all of the extended amplification template 160 is then achieved through 5' exonuclease activity (as in this example), or by elevated temperature, or by a restriction endonuclease (Figure 9g, 9h).

Once amplification moiety 152 has been sufficiently extended, it can be detected by hybridisation of Detection probes complementary to the repeats within the extended strand. Alternatively, secondary amplification templates, comprised in the 5'-3' direction of hybridisation region 161, extension blocker 153, and amplification moiety 173 are hybridised to extended amplification moiety 152 (Figures 9i, 9j). The hybridisation region can, if required, incorporate modified nucleotides (as in this example) to render it resistant to 5' double stranded exonuclease activity.

Amplification moiety 173 is then used as the target for an additional round of signal amplification performed as before using amplification template 180 comprised in the 5'-3' direction of hybridisation region 181 and extension region 182 (Figures 9j-9p). A final signal detection step is then performed (Figure 9q) which detects the extension region 181 of amplification template 180.

- 36 -

### CLAIMS

1. A method of detecting a target molecule (20), comprising the steps of:
  - i) contacting a sample with a locator probe (10,30) comprising a binding moiety (11,31) specific for said target molecule (20) and an amplification nucleic acid sequence (12,32) to produce a target molecule-locator probe complex;
  - ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe (10,30) with:
    - a) a single stranded amplification template (40,50) comprising:
      - i) arranged in a 5' to 3' direction:
        - a) an extension nucleic acid sequence (41,51);
        - b) a hybridisation nucleic acid sequence (42) complementary to the amplification nucleic acid sequence (12,32,52) of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence (41,51); and
      - c) an amplification moiety (43,53), being limited in all but the final repeat to a nucleic acid sequence; and
    - ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence.
  - b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence (12,32,53) of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence (41,51) of said amplification template (40,50);
  - c) a separating agent capable of removing sufficient of said extension nucleic acid sequence (41,51) of said amplification template (40,50) when hybridised to said complementary strand to allow subsequent hybridisation of said

- 37 -

hybridisation nucleic acid sequence (42,52) of said amplification template (40,50) to said complementary strand; and

d) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence (12,32,53) of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence (41,51) of said amplification template (40,50);

iii) detecting any bound amplification template (40,50) from the amplification step or steps; and

iv) correlating the results of detection step (iii) with the presence of said target molecule (20).

2. A method for detecting target molecule according to claim 1, the removal of said extension nucleic acid sequence (41,51) being achieved by the use of a 5' double stranded exonuclease against whose activity the hybridisation nucleic acid sequence (42,52) is protected.

3. A method for detecting a target molecule (20) comprising the steps of:

i) contacting a sample with a locator probe (110) comprising a binding moiety (111) specific for said target molecule (20) and an amplification nucleic acid sequence (112) to produce a target molecule-locator probe complex;

ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe (110) with:

a) a single stranded first amplification template (70,90) comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence (71,91);

- 38 -

b) a hybridisation nucleic acid sequence (72,92) complementary to the amplification nucleic acid sequence (93,103,112) of the previous amplification step or, where there is no previous amplification step, of the preceding step and having a substantially different sequence to said extension nucleic acid sequence (71,91); and

c) an amplification moiety (73,93), being limited in all but the final repeat to a nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence.

b) a single stranded second amplification template (80,100) comprising:

i) arranged in a 5' to 3' direction'

a) an extension nucleic acid sequence (81,101) comprising said hybridisation nucleic acid sequence (72,92) of said first amplification template (70,90);

b) a hybridisation nucleic acid sequence (82,102) comprising the extension nucleic acid sequence (71,91) of said first amplification template (70,90); and

c) an amplification moiety (83,103), being limited in all but the final amplification step to a nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

c) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence (93,103,112) of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence (71,81,91,101) of said first and second amplification templates (70,80,90,100);

d) a separating agent capable of removing sufficient of said extension nucleic acid sequence (71,81,91,101) of said first and second amplification templates (70,80,90,100) when hybridised to said complementary strand to allow

- 39 -

subsequent hybridisation of said hybridisation nucleic acid sequence (72,82,92,102) of said first and second amplification templates (70,80,90,100) to said complementary strand; and

e) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence (93,103,112) of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequences (71,81,91,101) of said first and second amplification templates (70,80,90,100);

iii) detecting any bound first and/or second amplification template (70,80,90,100) from the amplification step or steps; and

iv) correlating the results of detection step (iii) with the presence of said target molecule (20).

4. A method of detecting a target molecule (20) according to claim 3, the removal of said extension nucleic acid sequence (71,81,91,101) of said first and second amplification templates (70,80,90,100) being achieved by the use of a 5' double-stranded exonuclease against whose activity said hybridisation nucleic acid sequence (72,92) of said first amplification template (70,90) and said hybridisation nucleic acid sequence (82,102) of said second amplification template (80,100) are protected.

5. A method for detecting a target molecule (20) comprising the steps of:

i) contacting a sample with a locator probe (140) comprising a binding moiety (141) specific for said target molecule (20) and an amplification nucleic acid sequence (142) to produce a target molecule-locator probe complex, said amplification nucleic acid sequence (142) having one or more restriction sites for a restriction endonuclease when hybridised to a complementary strand;

ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe (140) with:

- 40 -

- a) a single stranded amplification template (120) comprising:
  - i) arranged in a 5' to 3' direction:
    - a) an extension nucleic acid sequence (121);
    - b) a hybridisation nucleic acid sequence (122) complementary to the amplification nucleic acid sequence (123,142) of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence (121); and
  - c) an amplification moiety (123), being limited in all but the final amplification step to a nucleic acid sequence; and
  - ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;
- b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence (123,142) of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence (121) of said amplification template (120);
- c) said restriction endonuclease; and
- d) the reagents and conditions necessary to:
  - i) effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence (123,142) of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence (121) of said amplification template (120); and
  - ii) effect dissociation of fragments of nucleic acid strands which have been cut by said restriction endonuclease activity from uncut complementary strands whilst not effecting dissociation of uncut nucleic acid strands from uncut complementary strands;

- 41 -

iii) detecting any bound amplification template (120) from the amplification step or steps; and

iv) correlating the results of detection step (iii) with the presence of said target molecule (20).

6. A method according to claim 5, said amplification nucleic acid sequence (123) and said hybridisation nucleic acid sequence (122) having nucleotide modifications which prevent cleavage by said restriction endonuclease, and said reagents including at least one modified nucleotide which, when incorporated into said complementary strand by said polymerising agent, prevent cleavage of said complementary strand by said restriction endonuclease.

7. A method according to claim 5, said hybridisation nucleic acid sequence having at least one nucleotide modification which prevents cleavage by said restriction endonuclease, said restriction endonuclease having single stranded nicking activity only.

8. A method according to claims 5-7, being performed isothermally.

9. A method according to claims 5-7, being performed at more than one temperature.

10. A method according to anyone of the preceding claims, the amplification step of step (ii) being performed two or more times.

11. A method for detecting a target molecule (20) comprising the steps of;

i) contacting a sample with a locator probe (150) comprising:

- a) a binding moiety (151) specific for said target molecule (20);
- b) an amplification nucleic acid sequence (152) to produce a

target molecule-locator probe complex; and

- 42 -

c) optionally comprising a signal moiety being other than a nucleic acid sequence;

ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said complex with:

a) a single stranded amplification template (160,180) comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence (162,182);

and

b) a hybridisation nucleic acid sequence (161,181) complementary to the amplification nucleic acid sequence (152,173) of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence (162,182); and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence (152,173) of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence (162,182) of said amplification template (160,180);

c) a separating agent capable of removing sufficient of said extension nucleic acid sequence (162,182) of said amplification template (160,180) when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation nucleic acid sequence (161,181) of said amplification template (160,180) to said complementary strand;

d) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence (152,173) of the previous amplification step or,

- 43 -

where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence (162,182) of said amplification template (160,180); and

iii) optionally repeating one or more times the steps of treating the products of the previous repeat or, where there is no previous repeat, the products of step (ii) with:

a) a separating agent capable of removing the remainder of said hybridisation nucleic acid sequence (161,181) of said amplification template (160,180) of the previous repeat or step (ii) when hybridised to said complementary strand;

b) an additional locator probe comprising:

i) a hybridisation nucleic acid probe (162,182) specific to said complementary strand of the previous repeat or step (ii);

ii) an amplification moiety (173), being limited in all but the final repeat to a nucleic acid sequence; and

to produce a complex; and

c) performing step (ii) as defined above, optionally using an amplification template (160,180) different to that which was previously used;

iv) detecting any bound additional locator probes or amplification template (160,180) from the amplification step or steps; and

v) correlating the results of detection step (iv) with the presence of said target molecule (20).

12. A method for detecting a target molecule (20) comprising the steps of;

i) contacting a sample with a locator probe (150) comprising a binding moiety (151) specific for said target molecule (20) and an amplification nucleic acid sequence (152) to produce a target molecule-locator probe complex;

ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said complex with:

- 44 -

a) a single stranded first amplification template (160,180) comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence (162,182);

and

b) a hybridisation nucleic acid sequence (161,181)

complementary to the amplification nucleic acid sequence (152,173) of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence ; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

b) a single stranded second amplification template comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence comprising said first amplification template hybridisation nucleic acid sequence; and

b) a hybridisation nucleic acid sequence comprising said first amplification template extension nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

c) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;

d) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said first and second amplification templates when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation nucleic acid sequence of said first and second amplification templates to said complementary strand;

e) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of

- 45 -

the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template;

iii) optionally repeating one or more times the steps of treating the products of the previous repeat or, where there is no previous repeat, the products of step (ii) with:

a) a separating agent capable of removing the remainder of said hybridisation nucleic acid sequences of said first and second amplification templates of the previous repeat or step (ii) when hybridised to said complementary strand;

b) an additional locator probe comprising:

i) a hybridisation nucleic acid probe specific to said complementary strand of the previous repeat or step (ii); and

ii) an amplification moiety, being limited in all but the final repeat to a nucleic acid sequence;

to produce a complex; and

c) performing step (ii) as defined above, optionally using an amplification template different to that which was previously used;;

iv) detecting any bound additional locator probes or amplification template from the amplification step or steps; and

v) correlating the results of detection step (iv) with the presence of said target molecule.

13. A method for detecting a target molecule according to either one of claims 11 or 12, the removal of said amplification template being achieved by the use of a 5' double strand specific exonuclease.

14. A method for detecting a target molecule according to either one of claims 11 or 12, the removal of said amplification template being achieved through the use of elevated temperature.

- 46 -

15. A method for detecting a target molecule according to claim 14, said locator probe being covalently attached to said target molecule prior to the removal of said amplification template.

16. A method for detecting a target molecule according to any one of claims 1-9, prior to said detection step additionally comprising performing a method according to steps (ii) and (iii) of either one of claims 11 or 12.

17. A method for detecting a target molecule according to any one of claims 1-9, said amplification moiety of said amplification template from said final amplification step comprising a nucleic acid sequence, and prior to said detection step additionally comprising performing steps (ii)-(iii) of a method according to either one of claims 11 or 12.

18. A method for detecting a target molecule according to any one of claims 11-15, prior to said detection step additionally comprising performing step (ii) of a method according to any one of claims 1, 3 or 5.

19. A method for detecting a target molecule according to any one of claims 11-15, said amplification moiety of said locator probe or additional locator probe from said final amplification step comprising a nucleic acid sequence, and prior to said detection step additionally comprising performing step (ii) of a method according to any one of claims 1, 3 or 5.

20. A method for detecting a target molecule according to any one of claims 1-9, 18 or 19, the step of detecting any bound amplification template comprising the steps of:

i) treating said sample, locator probe and amplification template or amplification templates with a detection probe which binds specifically to said amplification moiety of the last of said amplification templates; and

- 47 -

ii) detecting any bound detection probe.

21. A method for detecting a target molecule according to any one of claims 11-17, the step of detecting any bound amplification template comprising the steps of:

i) treating said sample, locator probe and amplification template with a detection probe which binds specifically to said amplification moiety of the last of said amplification templates; and

ii) detecting any bound detection probe.

22. A method according to either one of claims 20 or 21, the detection probe having a label which is detected by any one of the group of luminometry, fluorometry, spectrophotometry, and radiometry.

23. A method according to claim 22, the detection probe being labelled with any one of the group of, FAM (carboxyfluorescein), HEX (hexachlorofluorescein), TET (tetrachlorofluorescein), ROX (carboxy-X-rhodamine), TAMRA (carboxytetramethylrhodamine), JOE (carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein), or with biotin.

24. A method according to any one of the preceding claims, the amplification step being performed two or more times, each amplification step being performed using an amplification template having a different extension nucleic acid sequence, hybridisation nucleic acid sequence and amplification moiety to that of the amplification template used in the previous amplification step.

25. A method according to any one of the preceding claims, the target molecule to be detected being a nucleic acid sequence and the binding moiety of said locator probe comprising a nucleic acid sequence complementary to said target molecule nucleic acid sequence.

- 48 -

26. A method according to any one of the preceding claims, being performed using more than one locator probe, each locator probe having the same amplification nucleic acid sequence.
27. A method according to any one of the preceding claims, comprising two repeats.
28. A method according to any one of the preceding claims, unreacted reagents being removed at the end of step (i), each repeat, or detection step by washing.
29. A method according to claim 28, the unreacted reagents being selected from the group of locator probe, amplification template, and detection probe.

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

## PCT

To:

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20  
Switzerland

NOTIFICATION CONCERNING  
DOCUMENTS TRANSMITTED

Date of mailing  
(day/month/year)

19. 04. 02

International application No: PCT/GB 00/ 00921

This International Preliminary Examination Authority transmits herewith the following documents:

1. ☐ demand (Rule 61.1(a)).
2. ☒ copy of the international preliminary examination report and its annexes (Rule 71.1). *AS sent on 22.06.2001*
3. ☒ 1 other documents (*specify*): *Copy of form 1210 sent on 03.12.2001*

Name and mailing address of the IPEA/



European Patent Office  
D-80298 Munich  
Tel. (+49-89) 2399-0, Tx: 523656 epmu d  
Fax: (+49-89) 2399-4465

Authorized officer

**Michela Digiusto**  
CHURCHER G

Tel. (+49-89) 2399-2545





B.5818 - Patentlaan 2  
2280 HV Rijswijk (ZH)  
☎ +31 70 340 2040  
TX 31651 epo nl  
FAX +31 70 340 3016

Europäisches  
Patentamt

Eingangs-  
stelle

European  
Patent Office

Receiving  
Section

Office européen  
des brevets

Section de  
Dépôt

WIPO  
The International Bureau  
34, Chemin des Colombettes  
CH-1211 GENEVA 20  
SWITZERLAND

Datum/Date

03-12-2001

Zeichen/Ref./Réf.	Anmeldung Nr./Application No./Demande n°/Patent Nr./Patent No./Brevet n°. PCT/GB0000921 - EP/00909507.6-2116 /
Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire Tepnel Medical Limited	

For the aforementioned application, you are hereby notified that the EPO has not received:

( ) the notification of election (Rule 61.2 PCT)

☒ the copy of the international preliminary examination report  
(Art. 36(3)(a) PCT)

( ) the copy (copies) of the priority document(s) (Rule 17.2(a) PCT)

.....

.....

( ) .....

You are kindly requested to forward the missing item at your earliest convenience to the EPO in its capacity as designated/elected Office.

RECEIVING SECTION

-----  
In case the requested item is not available with the International Bureau, please indicate the reason and return Form 1210 to the EPO:

.....

The International Bureau



## PCT COOPERATION TREATY

PCT

NOTIFICATION CONCERNING  
SUBMISSION OR TRANSMITTAL  
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

MCNEIGHT & LAWRENCE  
Regent House  
Heaton Lane  
Stockport, Cheshire SK4 1BS  
ROYAUME-UNI

Date of mailing (day/month/year) 26 April 2000 (26.04.00)	
Applicant's or agent's file reference M98/0599/PCT	<b>IMPORTANT NOTIFICATION</b>
International application No. PCT/GB00/00921	International filing date (day/month/year) 13 March 2000 (13.03.00)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 12 March 1999 (12.03.99)
Applicant TEPNEL MEDICAL LIMITED et al	

1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.
3. An asterisk(\*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
4. The letters "NR" appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
12 Marc 1999 (12.03.99)	9905580.8	GB	07 Apri 2000 (07.04.00)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No. (41-22) 740.14.35	Authorized officer  Carlos Naranjo  Telephone No. (41-22) 338.83.38
--	---

003245954

# PATENT COOPERATION TREATY

PCT

## NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

From the INTERNATIONAL BUREAU

To:  
MCNEIGHT & LAWRENCE  
Regent House  
Heaton Lane  
Stockport, Cheshire SK4 1BS  
ROYAUME-UNI

Date of mailing (day/month/year) 21 September 2000 (21.09.00)		IMPORTANT NOTICE	
Applicant's or agent's file reference M98/0599/PCT			
International application No. PCT/GB00/00921	International filing date (day/month/year) 13 March 2000 (13.03.00)	Priority date (day/month/year) 12 March 1999 (12.03.99)	
Applicant TEPNEL MEDICAL LIMITED et al			

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:  
AU,KP,KR,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:  
AE,AL,AM,AP,AT,AZ,BA,BB,BG,BR,BY,CA,CH,CN,CR,CU,CZ,DE,DK,DM,EA,EE,EP,ES,FI,GB,GD,GE,GH,GM,HR,HU,ID,IL,IN,IS,JP,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MA,MD,MG,MK,MN,MW,MX,NO,NZ,OA,PL,PT,RO,RU,SD,SE,SG,SI,SK,SL,TJ,TM,TR,TT,TZ,UA,UG,UZ,VN,YU,ZA,ZW  
The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).
3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 21 September 2000 (21.09.00) under No. WO 00/55365

### REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

### REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer  J. Zahra
Facsimile No. (41-22) 740.1435	Telephone No. (41-22) 338.83.38

Continuation of Form PCT/IB/308

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF  
THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

<b>Date of mailing (day/month/year)</b> 21 September 2000 (21.09.00)	<b>IMPORTANT NOTICE</b>
<b>Applicant's or agent's file reference</b> M98/0599/PCT	<b>International application No.</b> PCT/GB00/00921
<p>The applicant is hereby notified that, at the time of establishment of this Notice, the time limit under Rule 46.1 for making amendments under Article 19 has not yet expired and the International Bureau had received neither such amendments nor a declaration that the applicant does not wish to make amendments.</p>	

## PATENT COOPERATION TREATY

PCT

INFORMATION CONCERNING ELECTED  
OFFICES NOTIFIED OF THEIR ELECTION

(PCT Rule 61.3)

From the INTERNATIONAL BUREAU

To:

MCNEIGHT & LAWRENCE  
Regent House  
Heaton Lane  
Stockport, Cheshire SK4 1BS  
ROYAUME-UNI

Date of mailing (day/month/year) 26 October 2000 (26.10.00)		IMPORTANT INFORMATION	
Applicant's or agent's file reference M98/0599/PCT			
International application No. PCT/GB00/00921	International filing date (day/month/year) 13 March 2000 (13.03.00)	Priority date (day/month/year) 12 March 1999 (12.03.99)	
Applicant TEPNEL MEDICAL LIMITED et al			

1. The applicant is hereby informed that the International Bureau has, according to Article 31(7), notified each of the following Offices of its election:

AP : GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW  
EP : AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
National : AU, BG, CA, CN, CZ, DE, IL, JP, KP, KR, MN, NO, NZ, PL, RO, RU, SE, SK, US


2. The following Offices have waived the requirement for the notification of their election; the notification will be sent to them by the International Bureau only upon their request:

EA : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
OA : BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
National : AE, AL, AM, AT, AZ, BA, BB, BR, BY, CH, CR, CU, DK, DM, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IN, IS, KE, KG, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, PT, SD,  
SG, SI, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

3. The applicant is reminded that he must enter the "national phase" **before the expiration of 30 months from the priority date** before each of the Offices listed above. This must be done by paying the national fee(s) and furnishing, if prescribed, a translation of the international application (Article 39(1)(a)), as well as, where applicable, by furnishing a translation of any annexes of the international preliminary examination report (Article 36(3)(b) and Rule 74.1).

Some offices have fixed time limits expiring later than the above-mentioned time limit. For detailed information about the applicable time limits and the acts to be performed upon entry into the national phase before a particular Office, see Volume II of the PCT Applicant's Guide.

The entry into the European regional phase is postponed **until 31 months from the priority date** for all States designated for the purposes of obtaining a European patent.

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No. (41-22) 740.14.35</p>	<p>Authorized officer: Zakaria EL KHODARY</p> <p>Telephone No. (41-22) 338.83.38</p> 
---	--

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

# PCT

To:

McNeight & Lawrence  
Regent House, Heaton Lane  
Stockport, Cheshire, SK4 1BS  
GRANDE BRETAGNE

## NOTIFICATION OF RECEIPT OF DEMAND BY COMPETENT INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

(PCT Rules 59.3(e) and 61.1(b), first sentence  
and Administrative Instructions, Section 601(a))

Date of mailing  
(day/month/year)

20. 10. 00

Applicant's or agent's file reference  
M98/0599/PCT

### IMPORTANT NOTIFICATION

International application No.

PCT/GB 00/00921

International filing date (day/month/year)

13/03/2000

Priority date (day/month/year)

12/03/1999

Applicant

TEPNEL MEDICAL LIMITED et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority considers the following date as the date of receipt of the demand for international preliminary examination of the international application:

02/10/2000

2. This date of receipt is:

- ☒ the actual date of receipt of the demand by this Authority (Rule 61.1(b)).
- ☐ the actual date of receipt of the demand on behalf of this Authority (Rule 59.3(e)).
- ☐ the date on which this Authority has, in response to the invitation to correct defects in the demand (Form PCT/IPEA/404), received the required corrections.

3. ☐ **ATTENTION:** That date of receipt is **AFTER** the expiration of 19 months from the priority date. Consequently, the election(s) made in the demand does (do) not have the effect of postponing the entry into the national phase until 30 months from the priority date (or later in some Offices) (Article 39(1)). Therefore, the acts for entry into the national phase must be performed within 20 months from the priority date (or later in some Offices) (Article 22). For details, see the *PCT Applicant's Guide*, Volume II.

- ☐ (If applicable) This notification confirms the information given by telephone, facsimile transmission or in person on:

4. Only where paragraph 3 applies, a copy of this notification has been sent to the International Bureau.

Name and mailing address of the IPEA/




European Patent Office  
D-80298 Munich  
Tel. (+49-89) 2399-0, Tx: 523656 epmu d  
Fax: (+49-89) 2399-4465

Authorized officer

CHURCHER G

Tel. (+49-89) 2399-2545



Attorney Docket No. 3551 P 055

Title: ENZYMATICALLY CATALYSED SIGNAL AMPLIFICATION

Page 6

smf 130056

---

Express Mail Label No. *EL 590 2592 76 US*

Date of Deposit: September 10, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to:  
COMMISSIONER FOR PATENTS, Washington, D.C. 20231  
(ATTN: BOX PCT/WITH FEE).

*Musum Frankh*

---

09/936382  
JC03 PCT/TO 10 SEP 2001

adhere. In addition, the many hybridisation steps involved in the assembly process render the system susceptible to the production of non-specific background signal.

The current invention outlines a method for the amplification of a nucleic acid based signal. It involves the generation of a repeating structure containing multiple copies of a detectable sequence, and is produced through the concerted action of a polymerase (which extends the repeating structure) and a separating agent (which uncovers hybridisation sites to allow assembly of sequence repeats). The method of the invention offers the following advantages over methods existing in the art:

1. It uses a small number of inexpensive components and so avoids the high cost per assay problems associated with other signal amplification systems such as bDNA.
2. It uses a signal amplification rather than a target amplification approach and thus it overcomes contamination problems associated with many current methodologies such as PCR.
3. It is an enzymatically catalyzed process that actively assembles the signal generating structure rather than relying on the passive hybridisation-based approaches of non-enzymatic methods such as bDNA.
4. It has the ability to address RNA and DNA targets with equal efficiency without pre-treatments, unlike for example PCR which requires an initial reverse transcription step before RNA targets can be amplified.
5. As the process is used in conjunction with a solid phase immobilized target it has the potential to be integrated into 'cutting edge' solid phase devices such as Biochips.

As can be seen from Figure 1a, Locator probe 10 comprises binding nucleic acid moiety 11 joined by a 5'-5' linkage to amplification moiety 12. Binding nucleic acid moiety 11 hybridises target nucleic acid sequence 21 of target molecule 20. Figure 1b shows Locator probe 30 comprising binding moiety 31 which is rendered resistant to exonuclease activity by the use of 2'-)-methyl-RNA residues in its synthesis, is joined by a 5'-3' linkage to amplification moiety 32. Binding nucleic acid moiety 31 hybridises target nucleic acid sequence 21 of target molecule 20.

Figure 2 shows primary amplification template 40 comprising arranged in a 5'-3' direction extension region 41, exonuclease-resistant hybridisation region 42 and amplification moiety 43.

In the method of the first embodiment of the present invention (Figure 3), hybridisation region 42 of amplification template 40 hybridises to amplification moiety 32 of Locator probe 30 (Figure 3a). DNA polymerase activity then causes the extension of amplification moiety 32, using extension region 40 as a template strand (Figure 3b). A 5' double-strand specific exonuclease (not shown) then digests the 5' terminus of the hybridised extension region 41. Exonuclease activity is halted when the enzyme encounters exonuclease resistant hybridisation region 42 (Figure 3c). Additional amplification template 40 is then able to hybridise to extended nucleic acid signal sequence 32 (Figure 3d) and the process of extension and exonuclease digestion proceed again to give the arrangement of Figure 3e.

Having washed the reaction mixture to remove unhybridized amplification template 40, the process is then repeated using secondary amplification template 50 comprising extension region 51, hybridisation region 52 and amplification moiety 53 (Figure 3f). Hybridisation region 52 is complementary to amplification moiety 43. The steps of extension of amplification moiety 43, digestion of extension region 51 and hybridisation of additional amplification template 50 then proceed as above, to create the Secondary Structure. This incorporates large numbers of amplification moiety 53 which are available for hybridisation (Figures 3g-3j).

substitutions such that its incorporation renders the newly synthesised strand resistant to restriction endonuclease activity.

Restriction endonuclease activity then nicks extension region 121. In an isothermal assay format the resultant fragments is designed so as to dissociate at the operating temperature used. In a thermocycled format the temperature is elevated to allow dissociation of the fragments without concomitant dissociation of uncleaved sequences. Additional amplification template 120 is then able to hybridise to extended amplification moiety 142 and the reaction able to proceed to assemble the Primary Structure. Detection or Secondary Structure assembly is subsequently carried out by repetition of the same basic processes as described above.

#### Example 4

In the fourth embodiment of the present invention (Figure 9), target nucleic acid sequence 21 of target molecule 20 is hybridised by Binding moiety 151 (which has nucleotide modifications to render it resistant to 5' double stranded exonuclease activity when required) of Locator probe 150 (Figure 9a). Amplification moiety 152 is linked to binding nucleic acid sequence 151 by extension blocker 153 (a 3' propanol addition) such that it has an exposed 3'-OH group. When amplification moiety 152 is acting as the template strand for the synthesis of a complementary strand, the extension blocker prevents the progress of any DNA polymerase beyond the end of the amplification moiety, thereby preventing the displacement of binding moiety 151 from target nucleic acid sequence 21. Once unbound Locator probe has been removed, binding moiety 151 is optionally cross-linked to target sequence 21 prior to Primary Structure assembly.

In use, hybridisation region 162 of amplification template 160 hybridises to amplification moiety 152 (Figure 9b). Hybridisation region 162 has an exposed 3'-OH group, as does amplification moiety 152. Extension region 163 then acts as a template strand for the extension of amplification moiety 152, which in turn acts as a template strand for the extension of hybridisation region 161 as far as extension

blocker 153 (Figure 9c). 5' double strand exonuclease activity can then digest extended amplification template 160 as shown in this example, leaving free extended amplification moiety 152 (Figure 9d). Alternatively the amplification templates can be completely removed through the use of elevated temperature. Additionally the amplification templates can be designed so as to contain modified and unmodified restriction sites that allow endonuclease cleavage to remove the extension region of the amplification template only.

Additional amplification template 160 is then able to hybridise to extended amplification moiety 152 (Figure 9e) and extension region 162 again able to act as template strand for the synthesis of a complementary strand, extending further amplification moiety 152. Similarly, amplification moiety 152 is able act as template strand for the extension of hybridisation region 161 (Figure 9f). Removal of part or all of the extended amplification template 160 is then achieved through 5' exonuclease activity (as in this example), or by elevated temperature, or by a restriction endonuclease (Figure 9g, 9h).

Once amplification moiety 152 has been sufficiently extended, it can be detected by hybridisation of Detection probes complementary to the repeats within the extended strand. Alternatively, secondary amplification templates, comprised in the 5'-3' direction of hybridisation region 162, extension blocker 153, and amplification moiety 173 are hybridised to extended amplification moiety 152 (Figures 9i, 9j). The hybridisation region can, if required, incorporate modified nucleotides (as in this example) to render it resistant to 5' double stranded exonuclease activity.

Amplification moiety 173 is then used as the target for an additional round of signal amplification performed as before using amplification template 180 comprised in the 5'-3' direction of hybridisation region 181 and extension region 182 (Figures 9j-9p). A final signal detection step is then performed (Figure 9q) which detects the extension region 181 of amplification template 180.

CLAIMS

1. A method of detecting a target molecule, comprising the steps of:

i) contacting a sample with a locator probe comprising a binding moiety specific for said target molecule and an amplification nucleic acid sequence to produce a target molecule-locator probe complex;

ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe with:

a) a single stranded amplification template comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence;

b) a hybridisation nucleic acid sequence complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence; and

c) an amplification moiety, being limited in all but the final repeat to a nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence.

b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;

c) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said amplification template when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation

nucleic acid sequence of said amplification template to said complementary strand; and

d) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template;

iii) detecting any bound amplification template from the amplification step or steps; and

iv) correlating the results of detection step (iii) with the presence of said target molecule.

2. A method for detecting target molecule according to claim 1, the removal of said extension nucleic acid sequence being achieved by the use of a 5' double stranded exonuclease against whose activity the hybridisation nucleic acid sequence is protected.

3. A method for detecting a target molecule comprising the steps of:

i) contacting a sample with a locator probe comprising a binding moiety specific for said target molecule and an amplification nucleic acid sequence to produce a target molecule-locator probe complex;

ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe with:

a) a single stranded first amplification template comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence;

b) a hybridisation nucleic acid sequence

complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding

step and having a substantially different sequence to said extension nucleic acid sequence;  
and

c) an amplification moiety, being limited in all but the final repeat to a nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence.

b) a single stranded second amplification template comprising:

i) arranged in a 5' to 3' direction'

a) an extension nucleic acid sequence comprising said hybridisation nucleic acid sequence of said first amplification template;

b) a hybridisation nucleic acid sequence comprising the extension nucleic acid sequence of said first amplification template; and

c) an amplification moiety, being limited in all but the final amplification step to a nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

c) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said first and second amplification templates;

d) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said first and second amplification templates when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation nucleic acid sequence of said first and second amplification templates to said complementary strand; and

e) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a

plurality of sequences complementary to said extension nucleic acid sequences of said first and second amplification templates;

iii) detecting any bound first and/or second amplification template from the amplification step or steps; and

iv) correlating the results of detection step (iii) with the presence of said target molecule.

4. A method of detecting a target molecule according to claim 3, the removal of said extension nucleic acid sequence of said first and second amplification templates being achieved by the use of a 5' double-stranded exonuclease against whose activity said hybridisation nucleic acid sequence of said first amplification template and said hybridisation nucleic acid sequence of said second amplification template are protected.

5. A method for detecting a target molecule comprising the steps of:

i) contacting a sample with a locator probe comprising a binding moiety specific for said target molecule and an amplification nucleic acid sequence to produce a target molecule-locator probe complex, said amplification nucleic acid sequence having one or more restriction sites for a restriction endonuclease when hybridised to a complementary strand;

ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe with:

a) a single stranded amplification template comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence;

b) a hybridisation nucleic acid sequence

complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence; and

- 40 -

- c) an amplification moiety, being limited in all but the final amplification step to a nucleic acid sequence; and
- ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;
- b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;
- c) said restriction endonuclease; and
- d) the reagents and conditions necessary to:
  - i) effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template; and
  - ii) effect dissociation of nucleic acid strands which have been cut by said restriction endonuclease activity from uncut complementary strands whilst not effecting dissociation of uncut nucleic acid strands from uncut complementary strands;
  - iii) detecting any bound amplification template from the amplification step or steps; and
  - iv) correlating the results of detection step (iii) with the presence of said target molecule.

6. A method according to claim 5, said amplification nucleic acid sequence and said hybridisation nucleic acid sequence having nucleotide modifications which prevent cleavage by said restriction endonuclease, and said reagents including at least one modified nucleotide which, when incorporated into said complementary strand

by said polymerising agent, prevent cleavage of said complementary strand by said restriction endonuclease.

7. A method according to claim 5, said hybridisation nucleic acid sequence having at least one nucleotide modification which prevents cleavage by said restriction endonuclease, said restriction endonuclease having single stranded nicking activity only.

8. A method according to claims 5-7, being performed isothermally.

9. A method according to claims 5-7, being performed at more than one temperature.

10. A method according to anyone of the preceding claims, the amplification step of step (ii) being performed two or more times.

11. A method for detecting a target molecule comprising the steps of;

- i) contacting a sample with a locator probe comprising:
  - a) a binding moiety specific for said target molecule;
  - b) an amplification nucleic acid sequence to produce a target molecule-locator probe complex; and
  - c) optionally comprising a signal moiety being other than a nucleic acid sequence;
- ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said complex with:
  - a) a single stranded amplification template comprising:
    - i) arranged in a 5' to 3' direction:
      - a) an extension nucleic acid sequence; and

b) a hybridisation nucleic acid sequence complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;

c) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said amplification template when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation nucleic acid sequence of said amplification template to said complementary strand;

d) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template; and

iii) optionally repeating one or more times the steps of treating the products of the previous repeat or, where there is no previous repeat, the products of step (ii) with:

a) a separating agent capable of removing the remainder of said hybridisation nucleic acid sequence of said amplification template of the previous repeat or step (ii) when hybridised to said complementary strand;

b) an additional locator probe comprising:

i) a hybridisation nucleic acid probe specific to said complementary strand of the previous repeat or step (ii);

- ii) an amplification moiety, being limited in all but the final repeat to a nucleic acid sequence; and
- to produce a complex; and
- c) performing step (ii) as defined above, optionally using an amplification template different to that which was previously used;
- iv) detecting any bound additional locator probes or amplification template from the amplification step or steps; and
- v) correlating the results of detection step (iv) with the presence of said target molecule.

12. A method for detecting a target molecule comprising the steps of;

- i) contacting a sample with a locator probe comprising a binding moiety specific for said target molecule and an amplification nucleic acid sequence to produce a target molecule-locator probe complex;
- ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said complex with:

- a) a single stranded first amplification template comprising:
  - i) arranged in a 5' to 3' direction:
    - a) an extension nucleic acid sequence; and
    - b) a hybridisation nucleic acid sequence complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence; and
  - ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;
- b) a single stranded second amplification template comprising:
  - i) arranged in a 5' to 3' direction:
    - a) an extension nucleic acid sequence comprising said first amplification template hybridisation nucleic acid sequence; and

- 44 -

b) a hybridisation nucleic acid sequence comprising said first amplification template extension nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

c) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;

d) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said first and second amplification templates when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation nucleic acid sequence of said first and second amplification templates to said complementary strand;

e) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template;

iii) optionally repeating one or more times the steps of treating the products of the previous repeat or, where there is no previous repeat, the products of step (ii) with:

a) a separating agent capable of removing the remainder of said hybridisation nucleic acid sequences of said first and second amplification templates of the previous repeat or step (ii) when hybridised to said complementary strand;

b) an additional locator probe comprising:

i) a hybridisation nucleic acid probe specific to said complementary strand of the previous repeat or step (ii); and

ii) an amplification moiety, being limited in all but the final repeat to a nucleic acid sequence;

- to produce a complex; and
- c) performing step (ii) as defined above, optionally using an amplification template different to that which was previously used;;
- iv) detecting any bound additional locator probes or amplification template from the amplification step or steps; and
- v) correlating the results of detection step (iv) with the presence of said target molecule.

13. A method for detecting a target molecule according to either one of claims 11 or 12, the removal of said amplification template being achieved by the use of a 5' double strand specific exonuclease.

14. A method for detecting a target molecule according to either one of claims 11 or 12, the removal of said amplification template being achieved through the use of elevated temperature.

15. A method for detecting a target molecule according to claim 14, said locator probe being covalently attached to said target molecule prior to the removal of said amplification template.

16. A method for detecting a target molecule according to any one of claims 1-9, prior to said detection step additionally comprising performing a method according to steps (ii) and (iii) of either one of claims 11 or 12.

17. A method for detecting a target molecule according to any one of claims 1-9, said amplification moiety of said amplification template from said final amplification step comprising a nucleic acid sequence, prior to said detection step additionally comprising performing steps (ii)-(iii) of a method according to either one of claims 11 or 12.

18. A method for detecting a target molecule according to any one of claims 11-15, prior to said detection step additionally comprising performing step (ii) of a method according to any one of claims 1, 3 or 5.

19. A method for detecting a target molecule according to any one of claims 11-15, said amplification moiety of said amplification template from said final amplification step comprising a nucleic acid sequence, and prior to said detection step additionally comprising performing step (ii) of a method according to any one of claims 1, 3 or 5.

20. A method for detecting a target molecule according to any one of claims 1-9, 18 or 19, the step of detecting any bound amplification template comprising the steps of:

- i) treating said sample, locator probe and amplification template or amplification templates with a detection probe which binds specifically to said amplification moiety of the last of said amplification templates; and
- ii) detecting any bound detection probe.

21. A method for detecting a target molecule according to any one of claims 11-17, the step of detecting any bound amplification template comprising the steps of:

- i) treating said sample, locator probe and amplification template with a detection probe which binds specifically to said amplification moiety of the last of said amplification templates; and
- ii) detecting any bound detection probe.

22. A method according to either one of claims 20 or 21, the detection probe having a label which is detected by any one of the group of luminometry, fluorometry, spectrophotometry, and radiometry.

23. A method according to claim 22, the detection probe being labelled with any one of the group of, FAM (carboxyfluorescein), HEX (hexachlorofluorescein), TET

(tetrachlorofluorescein), ROX (carboxy-X-rhodamine), TAMRA (carboxytetramethylrhodamine), JOE (carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein), or with biotin.

24. A method according to any one of the preceding claims, the amplification step being performed two or more times, each amplification step being performed using an amplification template having a different extension nucleic acid sequence, hybridisation nucleic acid sequence and amplification moiety to that of the amplification template used in the previous amplification step.

25. A method according to any one of the preceding claims, the target molecule to be detected being a nucleic acid sequence and the binding moiety of said locator probe comprising a nucleic acid sequence complementary to said target molecule nucleic acid sequence.

26. A method according to any one of the preceding claims, being performed using more than one locator probe, each locator probe having the same amplification nucleic acid sequence.

27. A method according to any one of the preceding claims, comprising two repeats.

28. A method according to any one of the preceding claims, unreacted reagents being removed at the end of step (i), each repeat, or detection step by washing.

29. A method according to claim 28, the unreacted reagents being selected from the group of locator probe, amplification template, and detection probe.

1/21





FIG.1






FIG.2

2/21



(a)



(b)

FIG.3

3/21

09/936382






FIG. 3




4/21




(e)

FIG.3




(f)

09/936382




(g)

FIG.3



(h)


09/936382



(i)

FIG.3

(j)





8/21






FIG. 4









FIG. 5


9/21

FIG.6


09/936382

10/21

FIG.6



(e1)



(e2)

FIG. 6






FIG. 7

09/936382

12/21




(a)




(b)

FIG. 8



(c)


FIG. 8



(d)




14/21

09/936382

FIG.9

09/936382

15/21

FIG. 9

16/21





FIG. 9

17/21





FIG. 9

18/21

09/936382





FIG. 9

19/21

09/936382







FIG.9



09/936382

20/21

FIG. 9

21/21

09/936382

FIG.10FIG.11

## SEQUENCE LISTING

&lt;110&gt; TEPNEL MEDICAL LIMITED

&lt;120&gt; ENZYMATICALLY CATALYSED SIGNAL AMPLIFICATION

&lt;130&gt; M98/0599/GB

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; GB9905580.8

&lt;151&gt; 1999-03-12

&lt;160&gt; 6

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 10

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: N.BstNB1  
recognition sequence

&lt;400&gt; 1

gagtcnnnnn

10

&lt;210&gt; 2

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Cytomegalovirus

&lt;220&gt;

<223> Description of Combined DNA/RNA Molecule:  
Endonuclease protected sequence

&lt;400&gt; 2

tcgacggtgg agatactgct gagg

24

&lt;210&gt; 3

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Amplification  
template

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (20)

- 2 -

&lt;223&gt; cm

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (21)

&lt;223&gt; um

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (22)

&lt;223&gt; cm

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (23)

&lt;223&gt; 2'-O-methyladenosine

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (24)

&lt;223&gt; gm

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (25)

&lt;223&gt; cm

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (26)

&lt;223&gt; 2'-O-methyladenosine

&lt;400&gt; 3

ttctccttcc agttgctacc ucagcagtat ctccac

36

&lt;210&gt; 4

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Combined DNA/RNA Molecule:  
Endonuclease protected sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Detection  
oligonucleotide

&lt;400&gt; 4

ttctccttcc agttgcta

18

&lt;210&gt; 5

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

- 3 -

<220>  
<223> Description of Artificial Sequence: Amplification  
template

<220>  
<221> modified\_base  
<222> (22)  
<223> cm

<220>  
<221> modified\_base  
<222> (23)  
<223> um

<220>  
<221> modified\_base  
<222> (24)  
<223> um

<220>  
<221> modified\_base  
<222> (25)  
<223> cm

<220>  
<221> modified\_base  
<222> (26)  
<223> cm

<220>  
<221> misc\_feature  
<222> (27)  
<223> 2'-O-methyladenosine

<400> 5  
gtgaagatgt tgcatgttct ccuuccagtt gctacc

36

<210> 6  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Detection  
oligonucleotide

<400> 6  
gtgaagatgt tgcatgtt

18

REC	26 JUN 2001
WIPO	PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

14

Applicant's or agent's file reference M98/0599/PCT	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB00/00921	International filing date (day/month/year) 13/03/2000	Priority date (day/month/year) 12/03/1999
International Patent Classification (IPC) or national classification and IPC C12Q1/68		
Applicant TEPNEL MEDICAL LIMITED et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 5 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 18 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  02/10/2000	Date of completion of this report  22.06.2001
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Barz, W  Telephone No. +49 89 2399 7320



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/00921

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17):*)

### Description, pages:

1,3-25,27-29, 32-35	as originally filed			
2,2a,30,31	as received on	14/04/2001	with letter of	10/04/2001
26	as received on	29/05/2001	with letter of	18/05/2001

### Claims, No.:

1-29	as received on	14/04/2001	with letter of	10/04/2001
------	----------------	------------	----------------	------------

### Drawings, sheets:

1/21-21/21	as originally filed
------------	---------------------

### Sequence listing part of the description, pages:

1-3, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/00921

the international application as filed has been furnished.

- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description,      pages:  
☐ the claims,      Nos.:  
☐ the drawings,      sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims 1-29
	No: Claims
Inventive step (IS)	Yes: Claims 1-29
	No: Claims
Industrial applicability (IA)	Yes: Claims 1-29
	No: Claims

2. Citations and explanations  
**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/GB00/00921

**ITEM I:**

The amendments to the the description and the claims fulfill the requirements of Article 34 (2)(b) PCT.

**ITEM V:**

Reference is made to the following document:

D1: US-A-5 451 503 (HOGAN J. J. et al.), 19 September 1995.

**1. NOVELTY**

The present application meets the requirements of Article 33(2) PCT, because none of the available prior art documents discloses a method of detecting a target molecule having the same combinations of features as those claimed in the present application.

**2. INVENTIVE STEP**

The present application also appears to meet the requirements of Article 33(3) PCT for the following reasons:

- 2.1 Document D1, which is considered to represent the closest prior art, discloses (see Example 14 and Figure 18) a method for detecting a target molecule, comprising steps (i) and (ii)(b), of **claim 1** of the present application. Compared to D1, the subject-matter of claim 1 differs by the use of a 3-part amplification template (step (ii)(a)), by the removal of the 5' terminus of the amplification template (step (ii)(c)) and by the extension of the 3' terminus of the locator probe (step (ii)(d)). The effect of said differences is that the amplification moiety of the locator probe is significantly amplified, thereby drastically increasing the number of binding sites for detection probes (see Figure 3(k)). D1 achieves the same effect (amplification of the detection sequence of strand 1, see Figure 18) in a

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/GB00/00921

different way. Therefore, the technical problem to be solved by claim 1 may be regarded as how to provide an alternative method for detecting a target molecule.

Since the available prior art does not appear to provide any indication to modify the method of D1 by using a 3-part amplification template (resulting in significant extension of the 3' terminus of the locator probe), the subject-matter of present claim 1 is considered inventive in the sense of Article 33(3) PCT.

2.2 Similarly, the subject-matter of **claim 3** also appears to involve an inventive step (Article 33(3) PCT), because the available prior art does not suggest the use of a second 3-part amplification template (the additional difference of claim 3 compared to D1). Therefore, it would not be obvious to the skilled person to modify the method of D1 by including two 3-part amplification templates, thereby resulting in the subject-matter of present claim 3.

2.3 The subject-matter of **claims 5 and 11** is considered inventive for analogous reasons, because the methods of these claims also involve the 3' extension of the locator probe by using amplification templates.

2.4 For analogous reasons as outlined in items 2.2 and 2.3 above, the subject-matter of **claim 12** also appears to involve an inventive step (Article 33(3) PCT).

2.5 **Claims 2, 4, 6-10, and 13-29** are dependent on claims 1, 3, 5, 11 and/or 12 and as such also meet the requirements of the PCT with respect to inventive step (Article 33(3) PCT).

### 3. INDUSTRIAL APPLICABILITY

The subject-matter of **claims 1-29** appears to be industrially applicable in the sense of Article 33(4) PCT.

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room 524  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE  
 ETATS-UNIS D'AMERIQUE  
 in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 26 October 2000 (26.10.00)	
<b>International application No.</b> PCT/GB00/00921	<b>Applicant's or agent's file reference</b> M98/0599/PCT
<b>International filing date</b> (day/month/year) 13 March 2000 (13.03.00)	<b>Priority date</b> (day/month/year) 12 March 1999 (12.03.99)
<b>Applicant</b> MULROONEY, Conor et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

02 October 2000 (02.10.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO          34, chemin des Colombettes          1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer          Zakaria EL KHODARY</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	---

PCT



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 7 :</b> <b>C12Q 1/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/55365</b> <b>(43) International Publication Date:</b> 21 September 2000 (21.09.00)
<b>(21) International Application Number:</b> PCT/GB00/00921 <b>(22) International Filing Date:</b> 13 March 2000 (13.03.00) <b>(30) Priority Data:</b> 9905580.8 12 March 1999 (12.03.99) GB <b>(71) Applicant (for all designated States except US):</b> TEPNEL MEDICAL LIMITED [GB/GB]; Scotscroft Building, Towers Business Park, 856 Wilmslow Road, Didsbury, Manchester, Cheshire M20 2RY (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> MULROONEY, Conor [IE/GB]; 8 Colonial Road, Heaviley, Stockport, Cheshire SK2 6PJ (GB). OULTRAM, John, Douglas [GB/GB]; 15 Granby Road, Stretford, Manchester, Cheshire M32 8JL (GB). <b>(74) Agent:</b> MCNEIGHT & LAWRENCE; Regent House, Heaton Lane, Stockport, Cheshire SK4 1BS (GB).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> ENZYMATICALLY CATALYSED SIGNAL AMPLIFICATION		
<b>(57) Abstract</b>  The present invention concerns detection of target molecules using methods of enzymatically catalysed amplification of target associated detectable structures.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## ENZYMATICALLY CATALYSED SIGNAL AMPLIFICATION

The present invention concerns detection of target molecules using methods of enzymatically catalyzed amplification of target associated detectable structures.

Several nucleic acid amplification techniques are already known, e.g. the Polymerase Chain Reaction (PCR). However many of these techniques (including PCR) suffer from the disadvantage that they specifically amplify a target sequence (amplicon) present within the sample of interest. This amplicon, once generated, can easily contaminate a laboratory working area in which strict controls are not maintained. Such contamination can render subsequent amplification reactions suspect, and can require a cessation of testing and the initiation of expensive decontamination procedures.

Techniques such as PCR, which detect the presence of a sequence by amplifying its number to detectable levels, are known as Target Amplification systems. In contrast, several techniques are known which amplify a signal to detectable levels, usually following the binding of a detector molecule to the molecule of interest, without amplification of said molecule. These are referred to as Signal Amplification techniques.

One such system Chiron Corporation (Urdea et al., US 5681697 and references cited therein) is known as the branched DNA system (bDNA). This system relies on the binding to the target molecule, of a large number of detector probes, which contain within their sequence a site for hybridisation of a non-target specific sequence. This sequence acts as the site for hybridisation of a pre-synthesized branched DNA structure with numerous sites for the hybridisation of secondary branches or of detection probes. One of the main disadvantages of this system is the large number of components required to generate the final structure to which the detection probes

adhere. In addition, the many hybridisation steps involved in the assembly process render the system susceptible to the production of non-specific background signal.

The current invention outlines a method for the amplification of a nucleic acid based signal. It involves the generation of a repeating structure containing multiple copies of a detectable sequence, and is produced through the concerted action of a polymerase (which extends the repeating structure) and a separating agent (which uncovers hybridisation sites to allow assembly of sequence repeats). The method of the invention offers the following advantages over methods existing in the art:

1. It uses a small number of inexpensive components and so avoids the high cost per assay problems associated with other signal amplification systems such as bDNA.
2. It uses a signal amplification rather than a target amplification approach and thus it overcomes contamination problems associated with many current methodologies such as PCR.
3. It is an enzymatically catalyzed process that actively assembles the signal generating structure rather than relying on the passive hybridisation-based approaches of non-enzymatic methods such as bDNA.
4. It has the ability to address RNA and DNA targets with equal efficiency without pre-treatments, unlike for example PCR which requires an initial reverse transcription step before RNA targets can be amplified.
5. As the process is used in conjunction with a solid phase immobilized target it has the potential to be integrated into 'cutting edge' solid phase devices such as Biochips.

c) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said amplification template when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation nucleic acid sequence of said amplification template to said complementary strand; and

d) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template;

iii) detecting any bound amplification template from the amplification step or steps; and

iv) correlating the results of detection step (iii) with the presence of said target molecule.

Reference in the various embodiments of the invention to "the preceding step" is typically reference to step (i) of the method, although it does include (see below) as a "preceding step" an amplification step (i.e. a step of producing an amplification structure) of a different embodiment of the invention.

The removal of said extension nucleic acid sequence may be achieved by the use of a 5' double stranded exonuclease against whose activity the hybridisation nucleic acid sequence is protected. The hybridisation nucleic acid sequence (and other sequences, as necessary) may be protected from exonuclease activity by substituting 2'-O-methyl RNA residues for normal residues during its synthesis.

In a second embodiment, the present invention provides a method for detecting a target molecule (using amplification templates whose extension and hybridisation regions differ so as to minimize interfering side reactions) comprising the steps of:

The target molecule may first be immobilized on a solid phase before employing the detection method of the present invention. The invention is not limited to this or any other specific assay format.

According to a first embodiment of the present invention there is provided a method for detecting a target molecule, comprising the steps of:

i) contacting a sample with a locator probe comprising a binding moiety specific for said target molecule and an amplification nucleic acid sequence to produce a target molecule-locator probe complex;

ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe with:

a) a single stranded amplification template comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence;

b) a hybridisation nucleic acid sequence

complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence; and

c) an amplification moiety, being limited in all but the final repeat to a nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence.

b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;

i) contacting a sample with a locator probe comprising a binding moiety specific for said target molecule and an amplification nucleic acid sequence to produce a target molecule-locator probe complex;

ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe with:

a) a single stranded first amplification template comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence;

b) a hybridisation nucleic acid sequence

complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having a substantially different sequence to said extension nucleic acid sequence; and

c) an amplification moiety, being limited in all but the final repeat to a nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence.

b) a single stranded second amplification template comprising:

i) arranged in a 5' to 3' direction'

a) an extension nucleic acid sequence comprising said hybridisation nucleic acid sequence of said first amplification template;

b) a hybridisation nucleic acid sequence comprising the extension nucleic acid sequence of said first amplification template; and

c) an amplification moiety, being limited in all but the final amplification step to a nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

c) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a

complementary strand to said extension nucleic acid sequence of said first and second amplification templates;

d) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said first and second amplification templates when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation nucleic acid sequence of said first and second amplification templates to said complementary strand; and

e) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequences of said first and second amplification templates;

iii) detecting any bound first and/or second amplification template from the amplification step or steps; and

iv) correlating the results of detection step (iii) with the presence of said target molecule.

The removal of said extension nucleic acid sequence of said first and second amplification templates may be achieved by the use of a 5' double-stranded exonuclease against whose activity said hybridisation nucleic acid sequence of said first amplification template and said hybridisation nucleic acid sequence of said second amplification template are protected.

#### Locator probe.

The locator probe contains two distinct regions, the target binding moiety and the amplification nucleic acid sequence. The function of the target binding moiety is to locate to and interact with the target molecule so as to become located at that point. The target binding moiety may comprise anything capable of specifically binding the target molecule. For example in the case of the target molecule being a nucleic acid sequence, the binding moiety may comprise a nucleic acid sequence complementary

to the target nucleic acid sequence. Alternatively, it may comprise RNA, a mixture of RNA and DNA or for example PNA. Alternatively, the binding moiety may comprise an antibody or an antigen binding fragment thereof specific to the target molecule (Harlow, E. and Lane, D., "Using Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, New York, 1998). Other binding mechanisms (for example involving covalent bonding) and reagents will be readily apparent to one skilled in the art. The amplification nucleic acid sequence comprises a nucleic acid sequence that is non-complementary to the target and should not bind to it, therefore rendering it accessible for later binding events. Where the target molecule is a nucleic acid sequence, the Locator probe may be constructed such that its target binding moiety and amplification nucleic acid sequence are oligonucleotides joined using a 5'-3' linkage, or alternatively using a 5'-5' linkage such that each region possessed an extendible free 3' end. Where the target binding moiety is an antibody or antigen binding fragment, the signal nucleic acid moiety may be covalently bound to it using methods known in the art (see, for example, Ito, W. and Kurosawa, Y., 1993, Journal of Biological Chemistry, 268(27): 20668-20675).

#### Primary amplification template and the Primary Structure.

The amplification template is designed to hybridize via its hybridisation region (its hybridisation nucleic acid sequence) to a complementary nucleic acid sequence. Under the appropriate reaction conditions the 3' end of this hybridized complement can be extended to create a complement to the extension region (the extension nucleic acid sequence) of the amplification template. Selective removal of the extension region of the amplification template then leaves a newly synthesized single stranded region to which an additional amplification template can hybridize. A repetition of the steps of hybridisation, extension and removal results in an extended structure composed of multiple repeats of the amplification template. To distinguish this structure from others which may be subsequently generated it is referred to as the Primary Structure. The amplification templates involved in its construction are referred to as primary amplification templates.

Within the Primary Structure are the amplification moieties of the incorporated primary amplification templates. These regions, being non-complementary to the target or Primary Structure, are available to be hybridized with appropriately labeled Detection probes.

If the hybridisation region of the primary amplification template is designed for example to be complementary to the amplification nucleic acid sequence of the Locator probe, then the Primary Structure would be attached to the Locator probe which itself would be attached to the target. Hybridisation of the Detection probes to the Primary Structure would therefore provide a linearly amplified number of signal generating sites linked to the target sequence.

Secondary amplification templates and the Secondary Structure.

As an alternative to providing hybridisation nucleic acid sequences for subsequent detection by e.g. detection probes, the primary template amplification moieties incorporated into the Primary Structure can act as complements to the hybridisation region of secondary amplification templates.

The hybridisation region (i.e. the second amplification template hybridisation nucleic acid sequence) is designed to be complementary to the amplification moiety of the primary amplification template. Under the appropriate reaction conditions the 3' end of the primary template amplification moiety can be extended to create a complement to the extension region of the secondary amplification template. Selective removal of the extension region of the secondary template then leaves a newly synthesized single stranded region to which an additional secondary amplification template can hybridize. A repetition of the steps of hybridisation, extension and removal results in multiple extended structures (composed of multiple repeats of the secondary template) attached to the Primary Structure. This structure is referred to as the Secondary Structure.

The incorporated amplification moieties of the secondary templates being non-complementary to the target, Primary Structure or Secondary Structure are available to be hybridized to by appropriately labeled Detection probes. Overall a non-linear increase in the number of target associated signal generating sites is provided by the generation of the Secondary structure.

Each reaction, which results in the assembly of a structure, is referred to as a repeat. The first repeat generates the Primary Structure, the second repeat the Secondary structure and so on. Tertiary and Quaternary structures etc. can be readily generated in this fashion by carrying out the appropriate number of repeats. The number of repeats carried out will depend on the application and will reflect the sensitivity required.

#### Separating Agents

The generation of the extended Primary or Secondary structure etc., relies on the removal of the extension region of the amplification template once the complement to that region has been made. The 'uncovering' of this newly synthesized strand provides a site for another amplification template to hybridize and thus continue the assembly process. Separating agents are responsible for removal of the extension region. These separating agents may include any one or combination of the following: a 5' double strand specific exonuclease (such as T7 gene 6 exonuclease, or Lambda exonuclease); a restriction endonuclease; an RNase (such as RNase H); elevated temperature; or chemical denaturation.

Selective removal of the extension region, whilst ensuring the other regions of the incorporated amplification template remain attached to the growing structure requires some means of controlling or limiting the action of the separating agents. Protection against exonuclease may be achieved through the use of nucleotide analogues or synthetic nucleic acid sequences (e.g., phosphorothioate linkages or 2'-O-Methyl

RNA respectively). The inclusion of these synthetic blockers can restrict the activity of the exonucleases to those areas where they are required.

The incorporation of modified linkages can also modify the activities of restriction enzymes, resulting in double stranded cleavage, single stranded nicking or non-restriction of restriction enzyme recognition sites composed of the same base sequence. Deoxynucleotide phosphorothioates, methylated nucleotides and boronated deoxynucleoside triphosphates are all examples of suitable analogues which when incorporated into recognition sites could modify the activities of their restriction enzymes.

The use of chimeric RNA:DNA Amplification templates allows the selective removal of defined portions of the Template using RNase H which acts on the RNA portion of RNA:DNA hybrids.

If in the first and second embodiment the separating agent is a 5' double strand specific exonuclease, the hybridisation region of the amplification templates and the 5' terminus of the Locator probe would be protected by the inclusion of modified linkages or synthetic nucleotide analogues. If the separation agent is RNase H then the extension region of the amplification templates would be composed at least in part of RNA whilst the hybridisation region would be composed of DNA. Where the separating agents have temperature optima of 37°C, they could be used in conjunction with a polymerase such as Klenow (exo-) polymerase. In such a case, the method may operate isothermally at 37°C. Alternatively, the method may of course be performed at more than one temperature.

If the separating agent used is a restriction endonuclease there is the potential to operate the system using a variety of formats, examples and advantages of which are given below:

1. The method may be performed isothermally to provide a rapid qualitative result, or to temperature cycle to provide a less rapid but quantitative result.
2. The method may be operated at temperatures higher than 37°C to provide temperature controlled stringency, (an important facility given the length and complexity of the Amplification templates used).
3. The activities of restriction endonucleases are defined, well characterized and sequence based, more so than exonucleases such as T7 gene exonuclease and Lambda exonuclease, whose substrate specificity can vary.
4. The combination and concerted action of restriction endonucleases and polymerases under a single set of reaction conditions has been demonstrated frequently.
5. The latitude in operating temperatures allows for a more flexible approach in design rationale, particularly with respect to using different materials such as PNA and 2'- O-Methyl RNA.

In the case of a separating agent being a restriction endonuclease, one or more restriction sites are incorporated in the extension and hybridisation regions of the amplification templates. Those sites in the hybridisation region may be protected by the incorporation of nucleotide analogues at the site of enzymatic cleavage. Those sites in the extension region are unmodified. Hybridisation of the amplification template and creation of a complement to the extension region results in the formation of double stranded recognition sites for the restriction enzymes. Use of one or more modified dNTPs in the reaction mix results in the newly synthesized strand being protected. The enzyme nicks the sites in the extension region of the amplification template and at the operating temperature used, or by elevating the temperature, the resultant fragments are dissociated. This provides a single stranded

site to which an additional amplification template can hybridize to continue the assembly process.

Restriction enzyme used as described above must belong to that group which is capable of nicking the unprotected strand of a hemi-modified enzyme recognition site. It is also important that the recognition site sequence is non-palindromic such that amplification templates which self hybridize are not substrates for double stranded cleavage by the restriction enzyme. An example of a suitable enzyme is BsoB1. It is also possible to use enzymes whose activity is naturally restricted to nicking of a single strand as opposed to double stranded cleavage. An example of this kind of enzyme is N.BstNB1 which has the recognition sequence of SEQ ID NO: 1. When such an enzyme is used, it is unnecessary to include dNTP analogues in the reaction mix to protect the newly synthesized strand.

If the method of the present invention is operated isothermally then the reaction is relatively rapid (compared to non-isothermal methods) but qualitative in the signal output generated. Thermocycling (whereby nicked fragments dissociated at a higher temperature than the operating temperature of the restriction enzyme) can be used to generate a signal output that provides quantitative information.

In a third embodiment, the present invention provides a method for detecting a target molecule, utilising a restriction enzyme and polymerase, and comprising the steps of:

- i) contacting a sample with a locator probe comprising a binding moiety specific for said target molecule and an amplification nucleic acid sequence to produce a target molecule-locator probe complex, said amplification nucleic acid sequence having one or more restriction sites for a restriction endonuclease when hybridised to a complementary strand;

- ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe with:

- a) a single stranded amplification template comprising:
  - i) arranged in a 5' to 3' direction:
    - a) an extension nucleic acid sequence;
    - b) a hybridisation nucleic acid sequence complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence; and
  - c) an amplification moiety, being limited in all but the final amplification step to a nucleic acid sequence; and
  - ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;
- b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;
- c) said restriction endonuclease; and
- d) the reagents and conditions necessary to:
  - i) effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template; and
  - ii) effect dissociation of nucleic acid strands which have been cut by said restriction endonuclease activity from uncut complementary strands whilst not effecting dissociation of uncut nucleic acid strands from uncut complementary strands;
  - iii) detecting any bound amplification template from the amplification step or steps; and

iv) correlating the results of detection step (iii) with the presence of said target molecule.

In particular, amplification step (ii) may be performed at least twice.

Said amplification nucleic acid sequence and said hybridisation nucleic acid sequence may have nucleotide modifications which prevent cleavage by said restriction endonuclease, and said reagents including at least one modified nucleotide which, when incorporated into said complementary strand by said polymerising agent, prevent cleavage of said complementary strand by said restriction endonuclease.

Said hybridisation nucleic acid sequence may have at least one nucleotide modification which prevents cleavage by said restriction endonuclease, said restriction endonuclease having single stranded nicking activity only.

In the first three embodiments of the present invention, where the amplification moiety is not a nucleic acid sequence (i.e. in the final repeat of the amplification step) it need not be located 3' to the hybridisation nucleic acid sequence. Instead it must be located sufficiently 3' to the extension nucleic acid sequence such that it is not separated from the hybridisation nucleic acid sequence by the separating agent.

For example, the amplification moiety may comprise a biotin molecule (detectable using standard techniques) conjugated to the hybridisation nucleic acid sequence, probably (but not necessarily) at its 3' end.

Alternatively, the amplification moiety may comprise a fluorophore. For example, a fluorophore/quencher technique (such as that of Molecular Beacons) may be employed (as used in, for example, fluorescent PCR). A quencher moiety may be conjugated to the 3' region of the extension nucleic acid sequence, and a fluorophore moiety conjugated to the 5' region of the hybridisation nucleic acid sequence, such

that when the extension nucleic acid sequence forms part of the amplification template fluorescence is quenched, and when the separating agent has caused the separation of the hybridisation and extension nucleic acid sequences, fluorescence occurs.

Similarly, the signal moieties of the present invention allow for the production of a signal as amplification structures are generated. It may be that it is only desirable to detect the production of the amplification structure when amplification is complete, in which case detection may be achieved without using any signal moieties. Alternatively, it may for example be desirable to have real-time signal generation as amplification proceeds, in which case a signal moiety such as a fluorophore/quencher combination located on the hybridisation and extension nucleic acid sequences as described above may be employed. This will allow for the generation of a detectable fluorescent signal as the separating agent removes the extension nucleic acid sequence from amplification templates.

Amplification templates may consist of fewer than the three regions. A fourth embodiment of the present invention uses amplification templates that comprise in the 5-3' direction an extension nucleic acid region and a hybridisation nucleic acid region. The 3' terminus of the amplification template is modified to prevent extension.

The steps of hybridisation, extension and separation can be applied as with the first and second embodiments to generate a Primary Structure. If the amplification templates do not contain modified linkages to protect the hybridisation region, then exonuclease digestion can continue until the amplification template is completely removed. The resultant structure will then consist of a single stranded extended Locator probe amplification moiety attached via the Locator probe binding moiety to the target sequence. This can be detected using a complementary labelled detection probe. If generation of a Secondary Structure rather than detection is required, the structure is instead contacted with an additional secondary probe comprising in the

5'-3' direction a hybridisation nucleic acid region and an amplification moiety. Any of this probe which remains unhybridized can be removed by washing prior to addition of secondary amplification templates and generation of the Secondary Structure.

As with the first embodiment, a single amplification template whose extension and hybridisation region sequences are substantially the same can be used, or as with the second embodiment two amplification templates whose extension and hybridisation region sequences are substantially different can be employed.

The Primary structure can also be generated using amplification templates composed of two regions (hybridisation and extension) and a restriction enzyme (as with the third embodiment). The resultant structure will consist of multiple repeats of the amplification template hybridisation region hybridised to the extended amplification moiety of the Locator probe. It will contain no amplification template amplification moieties.

In a fourth embodiment, the present invention provides a method for detecting a target molecule comprising the steps of:

- i) contacting a sample with a locator probe comprising:
  - a) a binding moiety specific for said target molecule;
  - b) an amplification nucleic acid sequence to produce a target molecule-locator probe complex; and
  - c) optionally comprising a signal moiety being other than a nucleic acid sequence;
- ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said complex with:
  - a) a single stranded amplification template comprising:
    - i) arranged in a 5' to 3' direction:
      - a) an extension nucleic acid sequence; and

b) a hybridisation nucleic acid sequence complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;

c) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said amplification template when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation nucleic acid sequence of said amplification template to said complementary strand;

d) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template; and

iii) optionally repeating one or more times the steps of treating the products of the previous repeat or, where there is no previous repeat, the products of step (ii) with:

a) a separating agent capable of removing the remainder of said hybridisation nucleic acid sequence of said amplification template of the previous repeat or step (ii) when hybridised to said complementary strand;

b) an additional locator probe comprising:

i) a hybridisation nucleic acid probe specific to said complementary strand of the previous repeat or step (ii);

- ii) an amplification moiety, being limited in all but the final repeat to a nucleic acid sequence; and
- to produce a complex; and
- c) performing step (ii) as defined above, optionally using an amplification template different to that which was previously used;
- iv) detecting any bound additional locator probes or amplification template from the amplification step or steps; and
- v) correlating the results of detection step (iv) with the presence of said target molecule.

It is also possible to carry out the amplification process using amplification templates comprising in a 5'-3' direction a hybridisation and extension region, and whose sequences differ from each other. In a fifth embodiment, the present invention provides a method for detecting a target molecule, utilising amplification templates whose hybridisation and extension sequences differ, and comprising the steps of:

- i) contacting a sample with a locator probe comprising a binding moiety specific for said target molecule and an amplification nucleic acid sequence to produce a target molecule-locator probe complex;
- ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said complex with:
  - a) a single stranded first amplification template comprising:
    - i) arranged in a 5' to 3' direction:
      - a) an extension nucleic acid sequence; and
      - b) a hybridisation nucleic acid sequence complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

b) a single stranded second amplification template comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence comprising said first amplification template hybridisation nucleic acid sequence; and

b) a hybridisation nucleic acid sequence comprising said first amplification template extension nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

c) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;

d) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said first and second amplification templates when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation nucleic acid sequence of said first and second amplification templates to said complementary strand;

e) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template;

iii) optionally repeating one or more times the steps of treating the products of the previous repeat or, where there is no previous repeat, the products of step (ii) with:

- a) a separating agent capable of removing the remainder of said hybridisation nucleic acid sequences of said first and second amplification templates of the previous repeat or step (ii) when hybridised to said complementary strand;
- b) an additional locator probe comprising:
  - i) a hybridisation nucleic acid probe specific to said complementary strand of the previous repeat or step (ii); and
  - ii) an amplification moiety, being limited in all but the final repeat to a nucleic acid sequence;  
to produce a complex; and
- c) performing step (ii) as defined above, optionally using an amplification template different to that which was previously used;;
- iv) detecting any bound additional locator probes or amplification template from the amplification step or steps; and
- v) correlating the results of detection step (iv) with the presence of said target molecule.

Hybridisation nucleic acid sequences of the amplification templates of the fourth and fifth embodiments may be modified such that they cannot be extended in a 3' direction by the polymerizing agent.

The removal of said primary amplification template may be achieved by the use of a 5' double strand specific exonuclease.

With the methods of the fourth and fifth embodiments, the removal of said primary amplification template may be achieved through the use of elevated temperature. In such a case, said locator probe may be covalently attached to said target molecule prior to the removal of said primary amplification template. In particular, covalent attachment may be achieved prior to hybridisation of amplification templates.

Prior to the detection step of the first, second and third embodiments a method of steps (i) to (iii) of the fourth or fifth embodiments of the invention may be performed

(at least so far as an amplification structure is generated), and vice versa with steps (i) and (ii) of the first, second and third embodiments. Where the amplification moiety in a final amplification step is a nucleic acid sequence then step (i) of the subsequent method may be omitted.

Thus in such a method for detecting a target molecule according to any one of the first, second and third embodiments, and where said amplification moiety of said amplification template from said final amplification step comprises a nucleic acid sequence, step (ii) of a method according to either one of the fourth or fifth embodiments may be additionally performed.

Similarly, in a method for detecting a target molecule according to any one of the fourth or fifth embodiments, prior to said detection step it may additionally comprise step (ii) of a method according to any one of the first, second or third embodiments.

With the first, second and third embodiments (and methods whose final amplification step or repeat involves such embodiments), the step of detecting any bound amplification template may comprise the steps of:

- i) treating said sample, locator probe and amplification template or amplification templates with a detection probe which binds specifically to said amplification moiety of said amplification templates; and
- ii) detecting any bound detection probe.

With the fourth and fifth embodiments (and methods whose final amplification step or repeat involves such embodiments), the step of detecting any bound additional locator probes may comprise the steps of:

- i) treating said sample, locator probe and amplification template with a detection probe which binds specifically to said additional locator probe; and
- ii) detecting any bound detection probe.

The detection probe may have a label which is detected by any one of the group of luminometry, fluorometry, spectrophotometry, and radiometry. For example, the detection probe may be labelled with any one of the group of FAM (carboxyfluorescein), HEX (hexachlorofluorescein), TET (tetrachlorofluorescein), ROX (carboxy-X-rhodamine), TAMRA (carboxytetramethylrhodamine), JOE (carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein), or with biotin.

Alternatively or additionally, the detection step may detect any optional signal moieties used in the method. As discussed above, such moieties may comprise fluorophore/quencher combinations (which when detected will comprise solely the fluorophore moiety) or they may for example comprise biotin molecules. The presence of signal moieties allows for the real-time detection of amplification as the methods of the present invention are performed, particularly when the signal moieties comprise fluorophores.

In the various embodiments of the present invention, the amplification step may be performed two or more times, each amplification step being performed using an amplification template having a different extension nucleic acid sequence, hybridisation nucleic acid sequence and amplification moiety to that of the amplification template used in the previous amplification step.

In the various embodiments of the present invention, the target molecule to be detected may be a nucleic acid sequence, the binding moiety of said locator probe comprising a nucleic acid sequence complementary to said target molecule nucleic acid sequence.

The various embodiments of the present invention may be performed using more than one locator probe, each locator probe having the same amplification nucleic acid sequence.

The various embodiments of the present invention may for example comprise two repeats.

Unreacted reagents used in the methods of the present invention may be removed at the end of step (i), each repeat, or detection step, by washing. The unreacted reagents being selected from the group of locator probe, amplification template, primary amplification template, secondary amplification template and detection probe.

The detection of primary and secondary structures generated using embodiments one to five of the invention can be achieved by several different methods.

For example, suitably labelled detection probes can hybridise to the amplification moieties of the amplification templates used in the final step of the first, second and third embodiments. In the fourth and fifth embodiments detection probes may hybridise amplification nucleic acid sequences of locator probes. This requires the use of a separating agent to remove remaining amplification template hybridisation regions, and for a detection probe to then be used which binds to the extended amplification moiety of the locator probe used in the previous repeat. When separation is achieved by denaturation then this additionally requires the use of covalent crosslinking as discussed above (using for example a cross-linking agent such as DZQ (diazirinidylbenzoquinone)).

Alternatively or additionally, the amplification templates may have an internal or 3' terminally located label (i.e. signal moiety) attached that becomes incorporated into the structures as they are generated.

As described above, the amplification templates can be so designed that a fluorophore label in the hybridisation region sequence is separated from a quencher label in the extension region during primary/secondary structure assembly. In this way real time generation of signal is possible.

The invention will be further apparent from the following description, with reference to the several figures of the accompanying drawings, which show, by way of example only, forms of detection of target molecules and signal amplification.

Of the Figures:

Figure 1 shows forms of Locator probes hybridised to target nucleic acid sequences;

Figure 2 shows an amplification template used in the first embodiment of the present invention;

Figure 3 shows a target molecule detection method according to the first embodiment of the present invention;

Figure 4 shows incorrect amplification template binding;

Figure 5 shows amplification templates used in the second embodiment of the present invention;

Figure 6 shows a target molecule detection method according to the second embodiment of the present invention;

Figure 7 shows an amplification template used in the method of the third embodiment of the present invention;

Figure 8 shows the method of the third embodiment of the present invention;

Figure 9 shows the method of the fourth embodiment of the present invention;

Figure 10 shows results from Example 6. Y-axis shows slope (A490/minute) from 0 (bottom) to 0.140 (top). X-axis shows (left to right) Positive 1, Positive 2, Negative Klenow and Negative T7; and

Figure 11 shows strand extension by SAEX1 and SAEX22. Y-axis shows slope (A490/minute) from 0 (bottom) to 0.200 (top). X-axis shows (far-right) control with no enzyme and (all other columns) positives.

#### DEFINITIONS

The term "antibody" in its various grammatical forms is used herein to refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope. Such molecules are also referred to as "antigen binding fragments" of immunoglobulin molecules.

Illustrative antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab', F(ab')<sub>2</sub> and F(v).

Antibodies and their use are well known in the art, for example as taught by Harlow, E. and Lane, D., "Using Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, New York, 1998

As used herein the term "nucleic acid" includes protein nucleic acid (PNA) (i.e. nucleic acids in which the bases are linked by a polypeptide backbone) as well as the naturally occurring nucleic acids (e.g. DNA and RNA), or analogues thereof, having a sugar phosphate backbone.

#### Example 1

As can be seen from Figure 1a, Locator probe 10 comprises binding nucleic acid moiety 11 joined by a 5'-5' linkage to amplification moiety 12. Binding nucleic acid moiety 11 hybridises target nucleic acid sequence 21 of target molecule 20. Figure 1b shows Locator probe 30 comprising binding moiety 31 which is rendered resistant to exonuclease activity by the use of 2'-)-methyl-RNA residues in its synthesis, is joined by a 5'-3' linkage to amplification moiety 32. Binding nucleic acid moiety 31 hybridises target nucleic acid sequence 21 of target molecule 20.

Figure 2 shows primary amplification template 40 comprising arranged in a 5'-3' direction extension region 41, exonuclease-resistant hybridisation region 42 and amplification moiety 43.

In the method of the first embodiment of the present invention (Figure 3), hybridisation region 42 of amplification template 40 hybridises to amplification moiety 32 of Locator probe 30 (Figure 3a). DNA polymerase activity then causes the extension of amplification moiety 32, using extension region 40 as a template strand (Figure 3b). A 5' double-strand specific exonuclease (not shown) then digests the 5' terminus of the hybridised extension region 41. Exonuclease activity is halted when the enzyme encounters exonuclease resistant hybridisation region 42 (Figure 3c). Additional amplification template 40 is then able to hybridise to extended nucleic acid signal sequence 32 (Figure 3d) and the process of extension and exonuclease digestion proceed again to give the arrangement of Figure 3e.

Having washed the reaction mixture to remove unhybridized amplification template 40, the process is then repeated using secondary amplification template 50 comprising extension region 51, hybridisation region 52 and amplification moiety 53 (Figure 3f). Hybridisation region 52 is complementary to amplification moiety 43. The steps of extension of amplification moiety 43, digestion of extension region 51 and hybridisation of additional amplification template 50 then proceed as above, to create the Secondary Structure. This incorporates large numbers of amplification moiety 53 which are available for hybridisation (Figures 3g-3j).

Detection probe 60 comprises signal detection nucleic acid sequence 61 complementary to amplification moiety 53, linked to biotin label molecule 62. After hybridisation of Detection probe 60 and washing to remove any unhybridized probe, biotin label molecules 62 are detected using standard techniques. The result of the detection step is then correlated with the presence of target sequence 21.

As can be seen from Figure 4, there are certain undesirable interactions that are possible between for example amplification moiety 32 of Locator probe 30 and extension region 41 of amplification template 40. Figure 4a shows extension region 41 hybridising to amplification moiety 32. This is then subject to exonuclease activity (Figure 4b) and, subsequently, hybridisation region 42 of amplification template 40 is able to hybridise to amplification moiety 32. However, since amplification template 40 no longer possesses an extension region 41, it is not possible to extend signal nucleic acid sequence 32 and no further Primary Structure assembly is possible.

### Example 2

Figure 5 shows pairs of amplification templates used in the method of the second embodiment of the present invention. Primary amplification template 70 comprises arranged in a 5' to 3' direction extension region 71, hybridisation region 72 and amplification moiety 73. Second primary amplification template 80 comprises arranged in a 5' to 3' direction extension region 81 (which has the same sequence as hybridisation region 72), hybridisation region 82 (which has the same sequence as extension region 71) and amplification moiety 73. Extension region 71 and hybridisation region 72 have substantially different sequences, such that they will not hybridise the same nucleic acid sequence. The first secondary amplification template 90 comprises arranged in a 5' to 3' direction extension region 91, hybridisation region 92 (which is complementary to amplification moiety 73 from the previous repeat) and amplification moiety 93. The second secondary amplification template 100 comprises arranged in a 5' to 3' direction extension region 101 (which has the same

sequence as hybridisation region 92), hybridisation region 102 (which has the same sequence as extension region 91) and amplification moiety 103. Extension region 91 and hybridisation region 92 have substantially different sequences, such that they will not hybridise the same nucleic acid sequence. Nucleic acid sequences 72, 82, 92 and 102 contain 2'-O-methyl-RNA substituted nucleic acid sequences, ensuring that they are resistant to 5' exonuclease activity.

In practice (Figure 6), target nucleic acid sequence 21 of target molecule 20 is hybridised by binding nucleic acid sequence 111 of Locator probe 110. Binding nucleic acid moiety 111 contains substituted nucleic acids that ensure that it is resistant to 5' exonuclease activity (Figure 6a). Hybridisation region 72 of first amplification template 70 then hybridises to amplification moiety 112 of Locator probe 110 (Figure 6b). Since extension region 71 is different to hybridisation region 72 it is unable to hybridise to amplification moiety 112.

DNA polymerase activity then extends the free 3'-OH end of amplification moiety 112 using extension region 71 as a template. 5' exonuclease activity then digests extension region 71 (Figure 6c).

At this point it is possible for extension region 71 of amplification template 70 to hybridise to extended amplification moiety 112 (Figure 6d, top). However, since extension region 71 is not protected from 5' exonuclease activity, it is digested, leaving extended amplification moiety 112 exposed (Figure 6e.1). The remains of partially digested amplification template 70 (comprising hybridisation region 72 and amplification moiety 73) are unable to hybridise to extended amplification moiety 112.

Alternatively (Figure 6d, bottom) hybridisation region 82 of amplification template 80 is able to hybridise to extended amplification moiety 112. Amplification moiety 112 is then further extended by DNA polymerase activity using extension region 81 as a template. Extension region 81 is then digested (Figure 6e.2) and assembly of the

Primary Structure continues, with hybridisation region 72 of amplification template 70 hybridising to the extended amplification moiety 112.

After washing to remove unhybridized amplification templates 70 and 80 Secondary Structure assembly is then performed using amplification templates 90 and 100. The Secondary Structure is then detected and the results of the detection correlated with the presence of the target molecule.

### Example 3

Figure 7 shows an amplification template used in an embodiment of the third embodiment of the present invention. Amplification template 120 comprises extension region 121, hybridisation region 122 having substantially the same nucleic acid sequence as extension region 121 (at least to the extent that they are both able to hybridise the same nucleic acid sequence), and amplification moiety 123. Extension region 121 and hybridisation region 122 each in this example having two restriction sites 130, the restriction sites of extension region 121 being such that when hybridised to a complementary sequence they are capable of being cleaved by restriction endonuclease activity. However, the restriction sites of hybridisation region 122 have 2'-O-methyl-RNA modified nucleotides such that they are not subject to restriction endonuclease activity.

Signal amplification using the method of the third embodiment of the present invention is achieved as shown in Figure 8. Binding nucleic acid sequence 141 of Locator probe 140 hybridises to target nucleic acid sequence 21 of target molecule 20. The Locator probe amplification moiety 142 is complementary to hybridisation region 122 of amplification template 120 but has 2'-O-methyl-RNA nucleotide substitutions such that it is not subject to restriction endonuclease activity. Hybridisation region 122 of amplification template 120 then hybridises to amplification moiety 142 (Figure 8a), which is then extended by DNA polymerase activity using extension region 121 as a template (Figure 8b). At least one of the solution phase dNTPs utilised by the polymerase is modified with 2'-O-methyl-RNA

substitutions such that its incorporation renders the newly synthesised strand resistant to restriction endonuclease activity.

Restriction endonuclease activity then nicks extension region 121. In an isothermal assay format the resultant fragments is designed so as to dissociate at the operating temperature used. In a thermocycled format the temperature is elevated to allow dissociation of the fragments without concomitant dissociation of uncleaved sequences. Additional amplification template 120 is then able to hybridise to extended amplification moiety 142 and the reaction able to proceed to assemble the Primary Structure. Detection or Secondary Structure assembly is subsequently carried out by repetition of the same basic processes as described above.

#### Example 4

In the fourth embodiment of the present invention (Figure 9), target nucleic acid sequence 21 of target molecule 20 is hybridised by Binding moiety 151 (which has nucleotide modifications to render it resistant to 5' double stranded exonuclease activity when required) of Locator probe 150 (Figure 9a). Amplification moiety 152 is linked to binding nucleic acid sequence 151 by extension blocker 153 (a 3' propanol addition) such that it has an exposed 3'-OH group. When amplification moiety 152 is acting as the template strand for the synthesis of a complementary strand, the extension blocker prevents the progress of any DNA polymerase beyond the end of the amplification moiety, thereby preventing the displacement of binding moiety 151 from target nucleic acid sequence 21. Once unbound Locator probe has been removed, binding moiety 151 is optionally cross-linked to target sequence 21 prior to Primary Structure assembly.

In use, hybridisation region 162 of amplification template 160 hybridises to amplification moiety 152 (Figure 9b). Hybridisation region 162 has an exposed 3'-OH group, as does amplification moiety 152. Extension region 163 then acts as a template strand for the extension of amplification moiety 152, which in turn acts as a template strand for the extension of hybridisation region 161 as far as extension

blocker 153 (Figure 9c). 5' double strand exonuclease activity can then digest extended amplification template 160 as shown in this example, leaving free extended amplification moiety 152 (Figure 9d). Alternatively the amplification templates can be completely removed through the use of elevated temperature. Additionally the amplification templates can be designed so as to contain modified and unmodified restriction sites that allow endonuclease cleavage to remove the extension region of the amplification template only.

Additional amplification template 160 is then able to hybridise to extended amplification moiety 152 (Figure 9e) and extension region 162 again able to act as template strand for the synthesis of a complementary strand, extending further amplification moiety 152. Similarly, amplification moiety 152 is able act as template strand for the extension of hybridisation region 161 (Figure 9f). Removal of part or all of the extended amplification template 160 is then achieved through 5' exonuclease activity (as in this example), or by elevated temperature, or by a restriction endonuclease (Figure 9g, 9h).

Once amplification moiety 152 has been sufficiently extended, it can be detected by hybridisation of Detection probes complementary to the repeats within the extended strand. Alternatively, secondary amplification templates, comprised in the 5'-3' direction of hybridisation region 162, extension blocker 153, and amplification moiety 173 are hybridised to extended amplification moiety 152 (Figures 9i, 9j). The hybridisation region can, if required, incorporate modified nucleotides (as in this example) to render it resistant to 5' double stranded exonuclease activity.

Amplification moiety 173 is then used as the target for an additional round of signal amplification performed as before using amplification template 180 comprised in the 5'-3' direction of hybridisation region 181 and extension region 182 (Figures 9j-9p). A final signal detection step is then performed (Figure 9q) which detects the extension region 181 of amplification template 180.

#### Example 5

The various embodiments (above) of the invention are modified insofar as extension nucleic acid sequences 41,52,71,81,121,162 and 182 are provided in the form of a loop motif. As a result the nucleotides within the loop motifs are unavailable for hybridisation to complementary nucleotides, for example in amplification nucleic acid sequences.

Thus the loop motifs prevent undesirable hybridisation of the extension nucleic acid sequences, the sequences only being exposed when the loop motif is linearised, i.e. by the action of a polymerizing agent such as DNA polymerase as it synthesizes a complementary strand to the extension nucleic acid sequence.

#### Example 6

Concerted action of T7 gene 6 exonuclease and Klenow (exo-) polymerase.

CMV-002 (SEQ ID NO: 2), a 24-mer sequence specific for a conserved region in the GlyB gene of CMV, was covalently linked to solid phase support and used as the target for the Amplification Template SA-EX1 (SEQ ID NO: 3). A Detection Oligonucleotide SA-B1 (SEQ ID NO: 4) was designed to hybridise to the site generated by SA-EX1 in combination with the concerted action of Klenow (exo-) polymerase and T7 gene 6 exonuclease.

Nucleotides 1 and 2 of SEQ ID NO: 3 contain phosphorothioate linkages. Nucleotides 20-26 of SEQ ID NO: 3 are 2'-O-Methyl RNA. Nucleotide 1 of SEQ ID NO: 4 has a biotin label attached. All oligos were supplied by Oswel (Southampton UK).

76 pmoles of SA-EX1 was added to 2mg of CMV-002 support in each of four 0.2 ml eppendorf tubes in a total volume of 40 ml of 1 x Klenow (exo-) buffer. Hybridisation was allowed to proceed at room temperature for 10 minutes with gentle mixing by inversion at 1 minute intervals.

To tubes A and B, 10 ml of 1 x Klenow buffer containing 10 units of Klenow (exo-) polymerase, 100 units of T7 gene 6 exonuclease and 2 ml of a 20mM dNTP mix was added. To tube C, 10 ml of the same mixture omitting the polymerase was added, and to tube D, 10 ml of the mixture, omitting the T7 exonuclease was added. Samples were gently mixed and incubated at 37°C for 15 minutes.

Samples were transferred to bottom fritted DARAS (RTM) columns (Tepnel Medical Limited, UK; [www.tepnel.com](http://www.tepnel.com)). 100 ml of 1 x Sample Buffer (50mM Sodium citrate, 80mM Sodium chloride, 8 mM Magnesium chloride, 10mM Tris.HCl pH 8.3) was dispensed through each column in triplicate.

50 ml of 1 x Sample Buffer containing 79 pmoles of SA-B1 was added to each column and the column contents mixed by periodic inversion for 10 minutes at room temperature. Columns were washed by passage of 100 ml of System Buffer (10 mM Tris.HCl, pH 8.3) through each in triplicate.

The presence of hybridised SA-B1 oligonucleotide was confirmed using the EDSA1 detect protocol on the DARAS (RTM) system. Results are presented in Figure 10 as the slope of the signal detected (absorbance change at 490 nm /minute).

#### Example 7

Strand extension by sequential hybridisation.

CMV-002 (SEQ ID NO: 2) was covalently linked to solid phase support and used as the target for the EDSA Amplification oligonucleotide SA-EX1 (SEQ ID NO: 3). A second Amplification Oligonucleotide, SA-EX22 (SEQ ID NO: 5), was designed to hybridise to the site generated by SA-EX1 through the concerted action of Klenow (exo-) polymerase and T7 exonuclease. A Detection oligonucleotide SA-B2 (SEQ

ID NO: 6) was designed to hybridise to the site generated by SA-EX22 through the concerted action of Klenow (exo-) polymerase and T7 exonuclease.

Nucleotides 1 and 2 of SEQ ID NO: 5 contain phosphorothioate linkages. Nucleotides 22-27 of SEQ ID NO: 5 are 2'-O-Methyl RNA. Nucleotide 1 of SEQ ID NO: 6 has a biotin label attached. All oligos were supplied by Oswel (Southampton UK). All enzymes and buffers were supplied by Amersham Life Sciences Inc.(UK)

10 pmoles of SA-EX1 was added to 2mg of CMV-002 support in each of six 0.2 ml eppendorf tubes in a total volume of 30 ml of 1 x Klenow (exo-) buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM DTT 50 mg/ml BSA). Hybridisation was allowed to proceed at room temperature for 10 minutes, with gentle mixing by inversion at one minute intervals. The solution phase was removed by aspiration, and 50 ml of 1 x Klenow Buffer added. After the beads settled, the upper phase was removed by aspiration. This was repeated two more times.

To tubes A - E, 30 ml of 1 x Klenow buffer containing 15 units of Klenow (exo-) polymerase, 100 units of T7 gene 6 exonuclease, 2 ml of a 20mM dNTP mix and 100 pmoles of SA-EX22 was added. To tube F, 30 ml of the same mixture omitting both the polymerase and the T7 exonuclease was added. Samples were gently mixed and incubated at 37°C for 30 minutes.

Samples were transferred to bottom fritted DARAS (RTM) columns. 100 ml of 1 x Sample Buffer (50mM Sodium citrate, 80mM Sodium chloride, 8 mM Magnesium chloride, 10mM Tris.HCl pH 8.3) was dispensed through each column in triplicate.

50 ml of 1 x Sample Buffer containing 1 pmoles of SA-B2 was added to each column and the column contents mixed by periodic inversion for 10 minutes at room temperature. Columns were washed by passage of 100 ml of System Buffer (10 mM Tris.HCl, pH 8.3 ) through each in triplicate.

The presence of labelled SA-B2 oligonucleotide was confirmed using the EDSA1 detect protocol on the DARAS (RTM) system. Results are presented in Figure 11 as the slope of the signal detected ( absorbance change at 490 nm /minute ).

CLAIMS

1. A method of detecting a target molecule, comprising the steps of:
  - i) contacting a sample with a locator probe comprising a binding moiety specific for said target molecule and an amplification nucleic acid sequence to produce a target molecule-locator probe complex;
  - ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe with:
    - a) a single stranded amplification template comprising:
      - i) arranged in a 5' to 3' direction:
        - a) an extension nucleic acid sequence;
        - b) a hybridisation nucleic acid sequence complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence; and
      - c) an amplification moiety, being limited in all but the final repeat to a nucleic acid sequence; and
    - ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence.
  - b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;
  - c) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said amplification template when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation

nucleic acid sequence of said amplification template to said complementary strand; and

d) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template;

iii) detecting any bound amplification template from the amplification step or steps; and

iv) correlating the results of detection step (iii) with the presence of said target molecule.

2. A method for detecting target molecule according to claim 1, the removal of said extension nucleic acid sequence being achieved by the use of a 5' double stranded exonuclease against whose activity the hybridisation nucleic acid sequence is protected.

3. A method for detecting a target molecule comprising the steps of:

i) contacting a sample with a locator probe comprising a binding moiety specific for said target molecule and an amplification nucleic acid sequence to produce a target molecule-locator probe complex;

ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe with:

a) a single stranded first amplification template comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence;

b) a hybridisation nucleic acid sequence

complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding

step and having a substantially different sequence to said extension nucleic acid sequence;  
and

c) an amplification moiety, being limited in all but the final repeat to a nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence.

b) a single stranded second amplification template comprising:

i) arranged in a 5' to 3' direction'

a) an extension nucleic acid sequence comprising said hybridisation nucleic acid sequence of said first amplification template;

b) a hybridisation nucleic acid sequence comprising the extension nucleic acid sequence of said first amplification template; and

c) an amplification moiety, being limited in all but the final amplification step to a nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

c) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said first and second amplification templates;

d) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said first and second amplification templates when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation nucleic acid sequence of said first and second amplification templates to said complementary strand; and

e) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a

plurality of sequences complementary to said extension nucleic acid sequences of said first and second amplification templates;

iii) detecting any bound first and/or second amplification template from the amplification step or steps; and

iv) correlating the results of detection step (iii) with the presence of said target molecule.

4. A method of detecting a target molecule according to claim 3, the removal of said extension nucleic acid sequence of said first and second amplification templates being achieved by the use of a 5' double-stranded exonuclease against whose activity said hybridisation nucleic acid sequence of said first amplification template and said hybridisation nucleic acid sequence of said second amplification template are protected.

5. A method for detecting a target molecule comprising the steps of:

i) contacting a sample with a locator probe comprising a binding moiety specific for said target molecule and an amplification nucleic acid sequence to produce a target molecule-locator probe complex; said amplification nucleic acid sequence having one or more restriction sites for a restriction endonuclease when hybridised to a complementary strand;

ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said sample and locator probe with:

a) a single stranded amplification template comprising:

i) arranged in a 5' to 3' direction:

a) an extension nucleic acid sequence;

b) a hybridisation nucleic acid sequence

complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence; and

c) an amplification moiety, being limited in all but the final amplification step to a nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;

c) said restriction endonuclease; and

d) the reagents and conditions necessary to:

i) effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template; and

ii) effect dissociation of nucleic acid strands which have been cut by said restriction endonuclease activity from uncut complementary strands whilst not effecting dissociation of uncut nucleic acid strands from uncut complementary strands;

iii) detecting any bound amplification template from the amplification step or steps; and

iv) correlating the results of detection step (iii) with the presence of said target molecule.

6. A method according to claim 5, said amplification nucleic acid sequence and said hybridisation nucleic acid sequence having nucleotide modifications which prevent cleavage by said restriction endonuclease, and said reagents including at least one modified nucleotide which, when incorporated into said complementary strand

by said polymerising agent, prevent cleavage of said complementary strand by said restriction endonuclease.

7. A method according to claim 5, said hybridisation nucleic acid sequence having at least one nucleotide modification which prevents cleavage by said restriction endonuclease, said restriction endonuclease having single stranded nicking activity only.

8. A method according to claims 5-7, being performed isothermally.

9. A method according to claims 5-7, being performed at more than one temperature.

10. A method according to anyone of the preceding claims, the amplification step of step (ii) being performed two or more times.

11. A method for detecting a target molecule comprising the steps of;

- i) contacting a sample with a locator probe comprising:
  - a) a binding moiety specific for said target molecule;
  - b) an amplification nucleic acid sequence to produce a target molecule-locator probe complex; and
  - c) optionally comprising a signal moiety being other than a nucleic acid sequence;
- ii) producing an amplification structure bound to any complex produced in the preceding step by performing one or more times the amplification step of treating said complex with:
  - a) a single stranded amplification template comprising:
    - i) arranged in a 5' to 3' direction:
      - a) an extension nucleic acid sequence; and

b) a hybridisation nucleic acid sequence complementary to the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step and having substantially the same sequence as said extension nucleic acid sequence; and

ii) optionally comprising at least one signal moiety being other than a nucleic acid sequence;

b) a polymerising agent capable of extending the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by synthesising a complementary strand to said extension nucleic acid sequence of said amplification template;

c) a separating agent capable of removing sufficient of said extension nucleic acid sequence of said amplification template when hybridised to said complementary strand to allow subsequent hybridisation of said hybridisation nucleic acid sequence of said amplification template to said complementary strand;

d) the reagents and conditions necessary to effect the action of said polymerising agent and separating agent to allow the extension of the 3' terminus of the amplification nucleic acid sequence of the previous amplification step or, where there is no previous amplification step, of the preceding step by the synthesis of a plurality of sequences complementary to said extension nucleic acid sequence of said amplification template; and

iii) optionally repeating one or more times the steps of treating the products of the previous repeat or, where there is no previous repeat, the products of step (ii) with:

a) a separating agent capable of removing the remainder of said hybridisation nucleic acid sequence of said amplification template of the previous repeat or step (ii) when hybridised to said complementary strand;

b) an additional locator probe comprising:

i) a hybridisation nucleic acid probe specific to said complementary strand of the previous repeat or step (ii);

# INTERNATIONAL SEARCH REPORT

National Application No

Pct/GB 00/00921

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 02580 A (TM TECHNOLOGIES INC) 22 January 1998 (1998-01-22) the whole document	1-29
A	US 5 451 503 A (HOGAN JAMES J ET AL) 19 September 1995 (1995-09-19) figures 15-18; examples 8-14	1-29
A	WO 97 42346 A (TEPNEL MEDICAL LTD ;MINTER STEPHEN JOHN (GB); OULTRAM JOHN DOUGLAS) 13 November 1997 (1997-11-13) the whole document	1-29
A	US 5 681 697 A (URDEA MICHAEL S ET AL) 28 October 1997 (1997-10-28) cited in the application the whole document	1-29

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 August 2000

Date of mailing of the international search report

04/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.

Authorized officer

Reuter 11

# INTERNATIONAL SEARCH REPORT

International Application No

CT/GB 00/00921

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9802580	A	22-01-1998	AU 4040097 A	09-02-1998
			CA 2259918 A	22-01-1998
			EP 0938588 A	01-09-1999
			US 5902724 A	11-05-1999
US 5451503	A	19-09-1995	AU 665062 B	14-12-1995
			AU 3586693 A	01-09-1993
			CA 2128530 A	05-08-1993
			DE 69328699 D	29-06-2000
			EP 0552931 A	28-07-1993
			JP 7503139 T	06-04-1995
			WO 9315102 A	05-08-1993
			US 5424413 A	13-06-1995
WO 9742346	A	13-11-1997	AU 2646497 A	26-11-1997
US 5681697	A	28-10-1997	AU 694468 B	23-07-1998
			AU 1303895 A	27-06-1995
			CA 2178598 A	15-06-1995
			EP 0731848 A	18-09-1996
			HU 74225 A	28-11-1996
			JP 9507024 T	15-07-1997
			WO 9516055 A	15-06-1995
			US 5635352 A	03-06-1997